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Summary 
This report is the sixth national report on the performance of the National Cervical Screening 
Program in Australia. Cervical screening services are provided as part of mainstream health 
services with general practitioners performing approximately 80% of Pap smears. The 
program is funded by the Australian Government, and the state and territory governments 
(AIHW & AACR 2002). 
This report presents statistics on the performance monitoring indicators agreed to by the 
National Advisory Committee to the program.  
Overview 
The major goals of the program are to reduce incidence and mortality through screening to 
detect abnormalities of the cervix early so that medical intervention can avert the possible 
progression to cervical cancer. 
The statistics in this report show that the program is continuing to be very successful in 
meeting this goal. The combined detection rate of both high- and low-grade abnormalities in 
2002 was approximately 1.8% (33,096) of all screens; consequently incidence of cervical 
cancer was halved among women aged 20–69 from 18.0 per 100,000 women in 1989 to 9.5 in 
2000 and the mortality rate has declined by 61% from 5.4 per 100,000 women in 1982 to 2.1 in 
2002. 
The participation level is currently around 61.0%; this is a decline from 63.4% reported in 
1998–1999. Part of the reason for the decline is in improvements in measurement by the 
screening programs of participation. However, the level of participation suggests that there 
is scope for further improvements in the rate of screening. This is of particular importance 
for Indigenous women; cervical cancer incidence was higher among Indigenous women than 
among non-Indigenous women in Queensland and the Northern Territory, the only 
jurisdictions for which adequate data were available (ABS & AIHW 2003).  
The other main features in this report are described below. 
Participation 
• From January 2001 to December 2002 there were 3,331,013 women screened in Australia 
for pre-cancerous changes to cervical cells; the target age group, 20–69 years, accounted 
for 98% of the women screened. These figures exclude women from the Northern 
Territory because data were unavailable. 
• The national participation rate for women aged 20–69 declined from 63.4% in 1998–1999 
to 61.3% in 1999-2000; since then the rate has stabilised at 61.0% for the 2000–2001 and 
2001–2002 reporting periods. 
Early re-screening 
• The recommended screening interval is 2 years following a negative smear. Of a cohort of 
women screened in February 2001 who had a negative Pap smear result, 29% were 
screened again within 21 months. It is not known what proportion of this early re-
screening is justified on clinical grounds. 
• There has been an improvement in the proportion of women following a normal Pap 
smear who are being re-screened within the recommended 2-year interval. For the 
February 2001 cohort the re-screening rate was 29%, while for the February 1999 and 2000 
cohorts it was 32%.  
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• A low-grade abnormality includes atypia, warty atypia, possible cervical intraepithelial 
neoplasia (CIN), equivocal CIN, and CIN 1. A high-grade abnormality is defined to 
include CIN 1/2, CIN 2 and CIN 3 or adenocarcinoma in situ. The ratio of histologically 
confirmed low-grade abnormalities to high-grade abnormalities was 1.26 for Australia in 
2002 compared with 1.34 in 2001; the ratio has fluctuated each year between 1.26 and 1.47 
since 1997. The 2001 and 2002 ratios did not include data for the Northern Territory.  
• In 2002, the National Cervical Screening Program detected 14,590 women in the target 
age group 20–69 years with high-grade abnormalities. The number of high-grade 
abnormalities detected per 1,000 women screened was highest in the younger age 
groups. For women under 30 years of age, the rate of high-grade abnormalities was over 
10 per 1,000 women screened whereas it was less than 2 per 1,000 women aged  
50–69 years. 
Incidence and mortality 
• In 2000 there were 89 new cases of micro-invasive cervical cancer for women of all ages; 
all but 3 of these women were in the target age group, 20–69 years. The highest detection 
rates were for women in the 30–34 and 45–49 age groups. 
• The number of new cases of cervical cancer in Australia has continued to decline. There 
were 745 new cases in Australia in 2000 compared with 1,072 detected in 1989 prior to the 
start of the screening program. 
• Cervical cancer is the 18th most common cause of cancer mortality in women, accounting 
for 227 deaths in 2002. Although there was some fluctuation from year to year, the age-
standardised mortality rate from cervical cancer declined between 1982 and 2002. For all 
women aged 20 years and over there was a decline from 5.1 deaths per 100,000 women in 
1982 to 2.1 per 100,000 in 2002. During the same period, for women in the target age 
group of 20–69 years, the rate declined from 5.4 per 100,000 to 2.1 per 100,000. 
• Women in the target age group from remote locations experienced relatively high 
incidence and mortality rates from cervical cancer compared with women in major cities. 
A contributor to the higher incidence and mortality rates in remote locations was the 
higher incidence (ABS & AIHW 2003) and mortality rates among Indigenous women 
who make up a greater proportion of the remote population than they do in the major 
cities. The cervical cancer mortality rate for Indigenous women was 14.9 per 100,000 
women aged 20–69 and 18.9 for women of all ages in the period 1999–2002. 
• Between the periods 1995–1998 and 1999–2002, the age-standardised cervical cancer 
mortality rate declined in all regions (major cities, regional and remote). 
• Prior to 1998, only Western Australia, South Australia and the Northern Territory had 
Indigenous mortality registration data of sufficient quality to be publishable. In 1998, 
Queensland’s coverage of Indigenous deaths reached an acceptable level to be included 
in the analysis of Indigenous mortality data. For these jurisdictions, in the period 
1999–2002 there were 24 deaths from cervical cancer among Indigenous women in the 
target age group (an age-standardised mortality rate of 14.9 per 100,000 women). This is 
almost six times the corresponding rate in non-Indigenous women (2.5 per 100,000 in 
1999–2002). However, these rates are based on relatively small numbers of cases and may 
be subject to large variability. 
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National cervical screening 
monitoring indicators 
This report monitors the performance of the National Cervical Screening Program using ten 
indicators which measure program activity, performance and outcome. They help measure 
changes in disease patterns and examine the contribution health interventions may have in 
preventing or reducing deaths. They can also be used to help evaluate screening or other 
health interventions.  
Screening indicators for the National Cervical Screening Program cover the areas of 
participation, early re-screening, low- and high-grade abnormality detection, incidence and 
mortality. These have been endorsed by the National Advisory Committee and state and 
territory cervical screening programs. A listing of the ten indicators and their definitions 
follows. The target age group for the National Cervical Screening Program is 20 to 69 years. 
Indicator 1: Participation rate for cervical screening 
Percentage of women screened in a 24-month period by 5-year age groups (20–24, 25–29,  
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69), for all ages (20–80+) and the target 
age group (20–69 years). 
Indicator 2: Early re-screening 
Proportion of women re-screened by number of re-screens during a 21-month period 
following a negative smear. 
Indicator 3: Low-grade abnormality detection  
Number of women with a histologically verified low-grade intraepithelial abnormality 
detected in a 12-month period as a ratio of the number of women with a histologically 
verified high-grade intraepithelial abnormality detected in the same period.  
Indicator 4: High-grade abnormality detection 
Detection rate for histologically verified high-grade intraepithelial abnormalities per 1,000 
women screened in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39,  
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age 
group (20–69 years, age-standardised).  
Indicator 5.1: Incidence of micro-invasive squamous cell carcinoma 
Incidence rate of micro-invasive squamous cell carcinoma per 100,000 estimated resident 
female population in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age 
group (20–69 years, age-standardised). 
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Indicator 5.2: Incidence of squamous, adenocarcinoma, adeno-squamous and 
other cervical cancer 
Incidence rate of squamous, adenocarcinoma, adeno-squamous and other cervical cancers 
per 100,000 estimated resident female population in a 12-month period by 5-year age groups 
(20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 
85+) and for the target age group (20–69 years, age-standardised). 
Indicator 6.1: Mortality 
Death rate from cervical cancer per 100,000 estimated resident female population in a  
12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,  
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years, age-
standardised). 
Periodic indicators 
Periodic indicators have been developed to report on issues that are of importance in 
monitoring the outcomes of the cervical screening program over a longer period of time than 
1 year. This longer period allows for a greater aggregation of information on issues that are 
subject to wide annual fluctuations and for a more confident and meaningful estimate of the 
outcomes. The periodic indicators presented in this report are based on a reporting period of 
4 years. 
Periodic incidence and mortality indicators by location 
Geographic region 
In all previous reports, analysis of incidence and mortality data by geographic region used 
the Rural, Remote and Metropolitan Areas (RRMA) classification. This classification was 
developed in 1994 by the then Department of Primary Industries and Energy and the then 
Department of Human Services and Health. It allows geographic regions to be classified into 
seven zones—two metropolitan, three rural and two remote zones.  
This report uses a more recent geographic classification in place of RRMA. The new system, 
known as the Australian Standard Geographical Classification (ASGC), groups geographic 
areas into five classes. These classes are based on Census Collection Districts (CDs) and 
defined using the Accessibility/Remoteness Index for Australia (ARIA). ARIA is a measure 
of the remoteness of a location from the services provided by large towns or cities. A higher 
ARIA score denotes a more remote location. The five classes of the ASGC classification, along 
with a sixth ‘Migratory’ class, are listed in Table 1. 
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Table 1: The Remoteness Areas for the ASGC Remoteness Classification 
Region Collection districts within region 
Major cities of Australia CDs with an average ARIA index value of 0 to 0.2 
Inner regional Australia CDs with an average ARIA index value greater than 0.2 and less than or equal to 2.4 
Outer regional Australia CDs with an average ARIA index value greater than 2.4 and less than or equal to 5.92 
Remote Australia CDs with an average ARIA index value greater than 5.92 and less than or equal to 10.53 
Very remote Australia CDs with an average ARIA index value greater than 10.53  
Migratory Areas composed of off-shore, shipping and migratory CDs 
Source: ABS 2001. 
The ASGC classification is not directly comparable to the RRMA classification. Accessibility 
is judged purely on distance to one of the urban centres. For example, the ASGC 
classification allocates Hobart to its second group (Inner regional Australia) and Darwin to 
its third group (Outer regional Australia), whereas the RRMA classification grouped them 
together with the other capital cities. 
Indicator 5.3: Incidence by location 
Incidence rate of cervical cancer per 100,000 estimated resident female population in a 4-year 
period by location and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,  
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years, age-
standardised). 
Indicator 6.2: Mortality by location 
Death rate from cervical cancer per 100,000 estimated resident female population in a 4-year 
period by location and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,  
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years, age-
standardised). 
Indicator 6.3: Indigenous mortality 
Death rate from cervical cancer per 100,000 estimated resident female population in a 4-year 
period by Indigenous status and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 
50–54, 55–59, 60–64, 65–69, 70–74, 75+) and for the target age group (20–69 years, age-
standardised). 
This indicator examines the patterns of mortality among Indigenous women.  
Identification of Indigenous status is still very fragmented and generally of poor quality in 
health data collections, and cervical screening data are no exception. Of the seven cervical 
screening indicators, only one indicator can be stratified by Indigenous status: mortality. 
Even for this, coverage is not complete. Only Western Australia, South Australia, the 
Northern Territory and Queensland are currently considered to have adequate coverage of 
Indigenous deaths in the registration of deaths. Therefore, only mortality data from these 
jurisdictions are analysed in this report. 
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Confidence intervals 
Where indicators include a comparison between states and territories, between time periods, 
between geographic location or between Indigenous and non-Indigenous women, a 95% 
confidence interval is presented along with the rates. This is because the observed value of a 
rate may vary due to chance even where there is no variation in the underlying value of the 
rate. The 95% confidence interval represents a range over which variation in the observed 
rate is consistent with this chance variation. These confidence intervals can be used as an 
approximate test of whether changes in a particular rate are consistent with chance variation. 
Where the confidence intervals do not overlap, the change in a rate is greater than that which 
could be explained by chance. Where the intervals do overlap, then changes in the rate may 
be taken as approximately consistent with variability due to chance.  
For example, the participation rate for Victoria in 2000–2001 was 64.2% with a confidence 
interval of 64.1% to 64.4%. The corresponding rate for 2001–2002 was 64.8% with a 
confidence interval of 64.7% to 64.9%. These two intervals do not overlap, so the difference 
between the 2000–2001 and 2001–2002 rates is larger than we would expect due to chance 
alone.  
Another example is the comparison between cervical mortality rates for women in the target 
group in the remote areas. In the period 1995 to 1998 there were 6.0 cervical cancer deaths 
per 100,000 women living in remote areas. This rate had a confidence interval of 3.9 to 8.7. 
The 1999–2002 rate for women living in remote areas was 3.0 per 100,000, with a confidence 
interval of 1.7 to 4.9. These confidence intervals overlap, so despite the relatively large 
difference between the two observed rates they are still consistent with chance variation. This 
arises from the fact that remote areas of Australia have small populations, resulting in small 
numbers of deaths from any specific cause, and these rates may fluctuate from year to year 
over time. This in turn leads to relatively wide confidence intervals for an observed death 
rate. 
It is important to note that this result does not imply that the difference between the two 
rates is definitely due to chance. Instead, an overlapping confidence interval represents a 
difference in rates which is too small to differentiate between a real difference and one which 
is due to chance variation. 
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Participation 
The major objective of the National Cervical Screening Program is to reduce morbidity and 
deaths from cervical cancer by detecting treatable pre-cancerous lesions before their 
progression to cancer. Through increased participation, more women with pre-cancerous 
abnormalities can be detected and treated before progression to cervical cancer, thus 
reducing morbidity. In addition, increased participation will lead to the detection of more 
women with early stages of cancer where treatment can reduce mortality. 
The program, through a variety of recruitment initiatives, actively targets women in the age 
group 20–69 years. The recommended screening interval for women in this target age group 
who have been sexually active at any stage in their lives is 2 years. Pap smears may cease at 
the age of 70 years for women who have had two normal Pap smears within the previous  
5 years. Women over 70 years who have never had a Pap smear, or who request a Pap smear, 
are screened. 
Some women in the target population are unlikely to require screening. They include: 
• those who have had a total hysterectomy with their cervix removed 
• those who have never been sexually active 
• women with a previously diagnosed gynaecological cancer. 
Participation rate calculations should, in principle, exclude all three groups from the data. In 
practice, the data are adjusted to remove women who have had a hysterectomy but the latter 
two groups cannot be excluded due to the lack of reliable data. 
State and territory programs have strategic plans in place to increase participation of women 
in cervical screening. Such strategies include targeting priority population groups including 
Indigenous women, rural and remote women, and women from culturally and linguistically 
diverse backgrounds. 
The objectives and usefulness of participation as an indicator are outlined below: 
• The participation indicator measures the proportion of the target population covered by 
the cervical screening program and the current screening policy of a 2-year interval.  
• The indicator is important in assessing the contribution of the cervical screening program 
to changes in incidence and mortality.  
• The indicator can be used as a means of evaluating recruitment practices, particularly if 
participation rates are analysed by demographic characteristics.  
• When this indicator is used in conjunction with others, it can be used to support analysis 
relating to target groups and screening intervals.  
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State- and territory-specific issues 
• Except for Victoria and the Australian Capital Territory, the participation rates are based 
on all women who were screened in that state or territory. This may lead to an over-
estimation of numbers of women screened because of double counting of some women 
between states. This may be the result of difficulty in identifying state of residence for 
women in border areas, and inclusion of women resident overseas.  
• The Western Australian participation rates for the period 2001–2002 includes all women 
screened in the state. In previous reports, participation rates referred to women resident 
in Western Australia only. 
• The Northern Territory data were unavailable for 2001–2002. Northern Territory data 
have been excluded from the national comparisons presented in Figures 1–4. 
 
Data issues 
• In 2001 the Australian Bureau of Statistics (ABS) carried out a full population census and 
a national health survey. These led to the revision of the ABS estimated resident 
population (ERP) data, the introduction of a new Australian standard population for use 
in age standardisation and the production of new estimates of hysterectomy status 
among Australian women. The denominators for participation rates presented in this 
report have been calculated using the 2001 ABS National Health Survey hysterectomy 
fractions and the revised ERP values and age-adjusted using the 2001 Australian 
standard population. The denominators for the equivalent rates in previous reports were 
calculated using the 1995 ABS National Health Survey hysterectomy fractions and 
unrevised ERP values and age-adjusted using the 1991 Australian standard population. 
The combined effect of these changes is that participation rates presented in this report 
are on average between 1 and 2 percentage points lower than equivalent rates in previous 
reports. 
• Recent fluctuations in participation rates over time and between jurisdictions may be 
influenced by improvements in record linkage procedures in the state and territory 
screening registers. These allow more accurate tracking of individual screening 
participants over time and may lead to an apparent decrease in recorded participation 
rates by up to 3 percentage points. There has also been variation over time and between 
jurisdictions in the use of short-term mass media campaigns which, in addition to any 
long-term effect, may have led to short-term fluctuations in screening participation.  
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Indicator 1: Participation rate for cervical screening 
Percentage of women screened in a 24-month period by 5-year age groups (20–24, 25–29, 
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the 
target age group (20–69 years). 
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 Refer to Tables 1b and 2b (pages 37 and 39). 
 Notes  
 1. Participation rates have been adjusted for the estimated proportion of women who have had a hysterectomy. 
 2. Northern Territory data were unavailable for 2001–2002 and they were excluded from 2000–2001 data for  
 comparison purposes. 
 3. These data exclude women who have opted not to be on the register. 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 1: Participation in the National Cervical Screening Program  
by age group, Australia, 2000–2001 and 2001–2002 
 
 
 Age group 
24-month 
period 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69
 (Per cent) 
2000–2001 50.2 61.0 64.8 64.8 64.4 65.0 63.0 64.9 55.3 46.8 61.0
2001–2002 49.9 60.2 64.1 64.4 64.3 65.4 63.0 65.7 56.1 48.0 61.0
Note: Northern Territory data were unavailable for 2001–2002. In this table and graph the Northern Territory data were excluded from data for 
2000–2001 for comparison purposes. 
• From January 2001 to December 2002 there were 3,331,013 women screened in Australia 
for pre-cancerous changes to cervical cells. Of these women, 3,262,574 (98%) were in the 
target age group 20–69 years (Table 2a, page 38). 
• The age-standardised participation rate for women aged 20–69 years was 61.0% in  
2000–2001 and 2001–2002 (Tables 1b and 2b, pages 37 and 39). 
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• Participation in 2001–2002 was lower among women aged in their twenties and sixties 
than in the other age groups in the target population. Although incidence for women in 
their twenties is relatively low, among women aged 30–34 it increases to 11.6 per 100,000 
women; therefore increasing participation and increasing detection rates of cervical 
abnormalities in women in their twenties would be likely to result in lower incidence of 
cervical cancer for women in their thirties. Screening is also very important for women in 
their sixties because they experience the highest incidence of cervical cancer in the target 
population with 15.9 and 14.8 per 100,000 women aged 60–64 and 65–69 respectively 
(Table 2b and 24, pages 39 and 65). 
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 Notes 
 1. Rates are expressed as the percentage of the eligible female population and age-standardised to the 
 Australian 2001 population. 
 2. Northern Territory data were unavailable for 2001–2002 and they were excluded from 2000–2001 data for  
 comparison purposes. 
 3. Bars on graphs represent 95% confidence intervals. 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 2: Participation (age-standardised) in the National Cervical Screening Program  
by women aged 20–69 years, states and territories, 2000–2001 and 2001–2002 
 
 
24-month 
period/ rate NSW Vic(a) Qld WA(b) SA Tas ACT(a) Australia
2000–2001     
AS rate 59.1 64.6 57.0 61.4 64.9 65.2 62.8 61.0
95% CI 59.0–59.3 64.5–64.8 56.8–57.1 61.2–61.6 64.6–65.1 64.7–65.6 62.3–63.4 60.9–61.1
2001–2002     
AS rate 59.4 64.9 56.3 60.7 65.2 65.0 63.3 61.0
95% CI 59.3–59.5 64.7–65.0 56.1–56.4 60.5–60.9 65.0–65.5 64.5–65.4 62.8–63.8 60.9–61.0
(a) The Victorian and Australian Capital Territory registries only register women with a Victorian or Australian Capital Territory address 
respectively. 
(b) Western Australian participation for 2001–2002 includes all women screened in that state, whereas in 2000–2001, and in all previous 
reports, the registry only registered women resident with a Western Australian address. 
Note: Northern Territory data were unavailable for 2001–2002. In this table and graph the Northern Territory data were excluded from data for 
2000–2001 for comparison purposes. 
• There were no significant increases in participation between 2000–2001 and 2001–2002 in 
any state or territory. Queensland’s and Western Australia’s participation rates were 
significantly lower in 2001–2002 than in the previous reporting period. 
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• Participation rates varied across the states and the Australian Capital Territory among 
women aged 20–69 years in 2001–2002, ranging from 65.2% in South Australia to a low of 
56.3% in Queensland. 
• The largest increase in participation between 2000–2001 and 2001–2002 occurred in the 
Australian Capital Territory with an increase of 0.5 percentage point but this increase 
was not statistically significant. 
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Early re-screening 
The National Cervical Screening Program seeks to maximise reductions in incidence and 
mortality for cervical cancer. The design of the screening program defines two key 
parameters for achieving these objectives—target populations and screening intervals. 
Compliance with these parameters is crucial to maintaining the effectiveness of the program 
and cost efficiency in order that resources may be used to increase population coverage. For 
most women who have a negative smear, the recommended interval before their next screen 
is 2 years.  
This indicator is defined as the repeating of a Pap smear within 21 months of a negative 
smear report. Reasons for the choice of 21 months as the time line for reporting are discussed 
under ‘Data issues’ below. 
This indicator: 
• tracks over a period of 21 months a cohort of women from all states and territories, 
except the Northern Territory, who had a negative smear result in February 2001 to 
determine the extent of early re-screening within the National Cervical Screening 
Program. The exception to this is Queensland where the index month is March. February 
was selected as the index month nationally because it has been shown to be a relatively 
stable month in terms of the number of women who are screened. This pattern has been 
consistent over a number of years, partly because fewer women take holidays at this 
time; 
• measures the compliance with the recommended screening interval following a negative 
smear; and  
• is important in assessing screening coverage around the recommended interval, as 
significant differences may reduce program effectiveness. 
This indicator should be interpreted with caution as some early re-screening after a negative 
Pap smear report is appropriate and in accordance with the National Health and Medical 
Research Council (NHMRC) guidelines. Specifically, if a woman has a history of 
histologically proven high-grade abnormality, then annual screening is recommended. If a 
woman is being monitored after treatment or during the resolution phase of a low-grade 
abnormality, it is appropriate for her to be screened earlier than the 24 months recommended 
screening interval.  
Data issues 
Northern Territory data were unavailable for the February 2001 to November 2002 reporting 
period in this report. The data for Indicator 2 published in reports before the Cervical 
Screening in Australia 1999–2000 report are not directly comparable with the data in this 
report as this indicator has been modified to change the follow-up period from 24 months to 
21 months. This change was made because women often have their Pap smear taken at a 
time convenient to them and are likely to have their biennial screening immediately before 
the 24-month anniversary. Also for some women, prescriptions for oral contraceptives lapse 
at 22 months and these women are then likely to combine their Pap smears with their visit to 
the GP for renewing their scripts for contraceptives. 
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Indicator 2: Early re-screening 
Proportion of women re-screened by number of re-screens during a 21-month period 
following a negative Pap smear. 
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 Refer to Table 4 (page 40). 
 Notes 
 1. The reference period for this indicator was the 21 months following the index months February 2000  
 and February 2001. 
 2. Northern Territory data were unavailable for the February 2001 to November 2002 cohort and for comparison  
 purposes were excluded from the February 2000 to November 2001 cohort. 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 3: Proportion of women re-screened by number of screens during the  
21-month period following a negative Pap smear in February 2001, Australia 
 
 
21-month period 0 screens 1 screen 2 screens 3+ screens 
 (Per cent) 
Feb 2000–Nov 2001 68.1 27.3 3.6 0.9 
Feb 2001–Nov 2002 70.7 25.4 3.1 0.8 
Note: Northern Territory data were unavailable for the February 2001 to November 2002 cohort and for comparison purposes were excluded from 
the February 2000 to November 2001 cohort. 
• A cohort of 170,145 women screened in February 2001 whose Pap smear results were 
normal was tracked over a 21-month period to measure the extent of early re-screening in 
Australia. Fewer women in the February 2001 cohort were re-screened early than in the 
previous cohort. 
• Of the February 2001 cohort, 29.3% were re-screened within 21 months, including 3.9% 
who were re-screened two or more times. 
• The proportion of women who did not have any additional Pap smears within 21 months 
following a negative result increased from 68.1% in 2000–2001 and to 70.7% in 2001–2002.  
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 Refer to Table 4 (page 40). 
 Notes 
 1. The reference period for this indicator was the 21 months following the index month February 2001.  
 2. Northern Territory data were unavailable for the February 2001 to November 2002 cohort and for comparison purposes  
 were excluded from the February 2000 to November 2001 cohort. 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 4: Proportion of women re-screened by number of screens during the 21-month 
period following a negative Pap smear in February 2001, states and territory 
 
 
No. of 
screens NSW Vic Qld WA SA Tas ACT Australia 
 (Per cent) 
0 screens 70.4 67.8 72.3 71.8 76.7 73.1 72.9 70.7 
1 screen 26.1 27.4 23.6 25.1 20.6 23.9 23.1 25.4 
2 or more 3.5 4.8 4.1 3.1 2.7 3.1 4.0 3.9 
Note: Northern Territory data were unavailable for the February 2001 to November 2002 cohort and for comparison purposes were excluded from 
the February 2000 to November 2001 cohort. 
• South Australia (76.7%), Tasmania (73.1%) and the Australian Capital Territory (72.9%) 
had the highest proportions of women who were not re-screened in the 21 months 
following their negative Pap smears in February 2001. 
• Victoria (32.2%) and New South Wales (29.6%) had the highest proportions of re-screens 
while the lowest proportion of re-screens within 21 months occurred in South Australia 
(23.3%).  
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Low-grade abnormalities 
The Pap smear test is able to identify a range of abnormalities in cervical cells. Some of these 
abnormalities have a greater chance of becoming malignant (the so-called high-grade 
abnormalities), and are therefore treated aggressively. The chance of low-grade 
abnormalities progressing to malignant change is very much less. 
In this report a low-grade intraepithelial abnormality includes:  
• atypia;  
• warty atypia (human papilloma virus (HPV) effect);  
• possible cervical intraepithelial neoplasia (CIN) (see Glossary);  
• equivocal CIN;  
• CIN 1; and  
• endocervical dysplasia not otherwise specified (NOS). 
The indicator is the ratio of low-grade to high-grade intraepithelial abnormalities, all 
histologically verified.  
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Indicator 3: Low-grade abnormality detection 
Ratio of number of women with a histologically verified low-grade intraepithelial 
abnormality detected in a 12-month period to the number of women with a histologically 
verified high-grade intraepithelial abnormality detected in the same period. 
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 Refer to Tables 5a and 5b (page 41). 
 Note: Northern Territory data were not available for 2001 and 2002. 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 5: Ratio of low- to high-grade abnormalities by women aged 20–69 years,  
states and territories, 2001 and 2002 
 
 
Year NSW Vic Qld WA SA Tas ACT Australia 
 (Ratio) 
2001 1.39 1.09 1.41 1.52 1.39 1.25 1.17 1.34 
2002 1.29 0.91 1.40 1.62 1.27 1.13 1.31 1.26 
Note: Northern Territory data were not available for 2001 and 2002. 
• The ratio of histologically confirmed low-grade abnormalities to high-grade 
abnormalities found in women aged 20–69 years in Australia declined from 1.34 in  
2001 to 1.26 in 2002.  
• In 2002 there was some variation between states and the Australian Capital Territory 
with the highest ratio in Western Australia (1.62), while Victoria (0.91) had the lowest 
ratio. 
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High-grade abnormalities 
High-grade lesions have a greater probability of progressing to invasive cancer than do low-
grade lesions. Therefore one of the aims of the National Cervical Screening Program is to set 
a screening interval that detects most of these lesions before they progress and become 
invasive. This indicator measures the frequency of this type of abnormality in the screened 
community. A high-grade intraepithelial abnormality is defined in this report as CIN 1/2, 
CIN 2, CIN 3 or adenocarcinoma in situ.  
The National Health and Medical Research Council has produced guidelines to assist in the 
management of women who have low- and high-grade intraepithelial abnormalities (DHSH 
1994b). These are summarised in Appendix F. 
State- and territory-specific issues 
• The reference period for Indicator 4 was the 12 months from January to December 2002 
for all states and the Australian Capital Territory. The Northern Territory was unable to 
provide data for 2001 and 2002. 
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Indicator 4: High-grade abnormality detection 
Detection rate for histologically verified high-grade intra-epithelial abnormalities per 
1,000 women screened in a 12-month period by 5-year age groups (20–24, 25–29, 30–34,  
35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target 
age group (20–69 years, age-standardised). 
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 Refer to Tables 6a and 6b (pages 42 and 43). 
 Notes 
 1. Northern Territory data were not available for 2001 and 2002. 
 2. The reference period for this indicator is from January to December 2002. 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 6: High-grade abnormalities per 1,000 women by age group,  
Australia, 2001 and 2002 
 
 
 Age group 
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69* 
 (Number per 1,000 women) 
2001 16.3 15.6 10.1 6.6 4.4 3.0 1.8 1.5 1.5 1.6 6.9 (6.8–7.0) 
2002 18.8 16.6 11.3 6.9 4.8 3.0 2.0 1.7 1.3 1.4 7.5 (7.4–7.6) 
*Age-standardised rates (standardised to the Australian 2001 population) with 95% confidence intervals. 
Note: Northern Territory data were not available for 2001 and 2002. 
• In 2002, there were 14,590 histologically verified high-grade abnormalities detected in 
1,849,294 women screened in the target age range 20–69 years (0.8%), compared with a 
0.7% detection rate in 2001 (Table 7b, page 45). 
• The age-standardised detection rate for histologically verified high-grade intraepithelial 
abnormalities increased from 6.9 per 1,000 women in the target age group, 20–69 years, in 
2001 to 7.5 per 1,000 women screened in 2002. 
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• The age-specific detection rate of high-grade intraepithelial abnormalities for women 
aged 20–69 years increased between 2001 and 2002 in all age groups except for falls in the 
oldest age groups 60–64 and 65–69, and except for women aged 45–49 where there was 
no change.  
• The rate of high-grade abnormalities detected was much higher in the younger age 
groups. In the 20–24 age group the rate was 18.8 per 1,000 women screened compared 
with less than 2 per 1,000 women aged 55–69 years. This age-specific distribution is the 
inverse of the pattern for cervical cancer mortality. 
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 Refer to Tables 9a and 9b (page 48). 
 Notes 
 1. The reference period for this indicator is from January to December 2002. 
 2. Rates are standardised to the 2001 Australian total population. 
 3. Northern Territory data were not available for 2001 and 2002. 
 4. Bars on graphs represent 95% confidence intervals. 
 Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 Figure 7: Age-standardised rate of high-grade abnormalities per 1,000 women  
screened aged 20–69 years, states and territories, 2001 and 2002 
 
 
AS rate NSW Vic Qld WA SA Tas ACT Australia 
2001 7.1 5.4 8.2 7.4 6.3 9.5 7.0 6.9 
95% CI 6.9–7.3 5.2–5.6 7.9–8.6 7.0–7.8 5.9–6.8 8.6–10.4 6.2–8.0 6.8–7.0 
2002 7.9 6.3 8.7 7.9 6.2 8.9 7.1 7.5 
95% CI 7.7–8.1 6.1–6.5 8.4–9.0 7.5–8.3 5.8–6.6 8.1–9.8 6.3–8.1 7.4–7.6 
Note: Northern Territory data were unavailable for 2001 and 2002. 
• The national rate of high-grade abnormalities found in women aged 20–69 years 
increased significantly from 6.9 per 1,000 women screened in 2001 to 7.5 in 2002. 
• In 2002, Tasmania had the highest rate of 8.9 high-grade abnormalities detected per 1,000 
women screened, while South Australia had the lowest with 6.2 for women in the target 
age group, 20–69 years. 
• Detection of high-grade abnormalities increased between 2001 and 2002 in all states with 
the exception of South Australia and Tasmania.  
• The increases in high-grade abnormalities observed in New South Wales and Victoria 
were statistically significant. 
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Incidence 
A major objective of the National Cervical Screening Program is to minimise the incidence of 
cervical cancer by detecting treatable pre-cancerous lesions before their progression to 
cancer. However, where these pre-cancerous lesions cannot be detected, diagnosis of cancer 
at its earliest stage, the micro-invasive stage, is the most desirable alternative. The next two 
indicators measure the incidence rates of micro-invasive and all cervical cancers in the 
community. Data on cervical cancer incidence are collated by the AIHW from state and 
territory cancer registries. 
In 1994 the International Federation of Gynaecology and Obstetrics endorsed the following 
definition of micro-invasive carcinoma of the cervix: 
Stage 1a1. Measured invasion of stroma no greater than 3 mm in depth and no wider than  
7 mm. 
Stage 1a2. Measured invasion of stroma between 3 mm and 5 mm in depth and no wider 
than 7 mm. The depth of invasion should be measured from the base of the 
epithelium, either surface or glandular, from which it originates. Vascular space 
involvement, either venous or lymphatic, should not alter the staging (Ostor & 
Mulvany 1996). 
In interpreting cervical cancer incidence statistics, note that cervical screening has been 
available on an ad hoc basis since the 1960s, but it is only since the late 1980s and early 1990s 
that there has been an organised national approach to screening at a population level. The 
introduction of cervical screening programs which achieve higher participation rates may 
result in the paradox whereby in the short term the number of new cases of micro-invasive 
cancer increases because cancers are found earlier than they would have been without 
screening, with the rate of more advanced cancers decreasing in the longer term.  
For this report the most recent national data available on incidence are for 2000, in contrast to 
screening data which are available for 2001. This time lag in availability of incidence data is 
expected to reduce over the next 2 years. 
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Indicator 5.1: Incidence of micro-invasive cervical 
cancer 
Incidence rates of micro-invasive squamous cell carcinoma per 100,000 estimated resident 
female population in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age 
group (20–69 years, age-standardised). 
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 Refer to Table 11 (page 50). 
 Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 8: Age-standardised incidence rates for micro-invasive squamous cell  
cancer, women aged 20–69 years, Australia, 1989–2000 
 
 
 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
 (Number per 100,000 women) 
AS rate 1.8 2.8 2.9 2.8 2.6 3.0 3.2 2.5 2.0 2.1 1.5 1.4
 
• The age-standardised incidence rate of micro-invasive cervical cancer was 1.4 per 100,000 
women in 2000 for women in the target age group of 20–69 years and 0.9 per 100,000 for 
women of all ages (Table 11, page 50). The rates have been declining since 1995. 
• In 2000 there were 89 new cases of micro-invasive cervical cancers for all women and 86 
new cases in women aged 20–69 years (Table 10, page 49). 
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 Note: Rates are expressed per 100,000 women. 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 9: Age-specific incidence rates of micro-invasive squamous cell cancer, women 
aged 20–69 years, Australia, 1999 and 2000 
 
 
 Age group 
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69* 
1999 0.3 1.9 2.0 2.6 2.1 1.1 1.2 1.8 0.5 0.9 1.5 (1.2–1.9) 
2000 0.2 1.7 3.5 1.9 1.0 2.2 0.8 0.8 0.8 0.0 1.4 (1.1–1.7) 
*Age-standardised rates (standardised to the Australian 2001 population) with 95% confidence intervals. 
 
• The age-standardised incidence rate of micro-invasive squamous cell cancer was 1.4 per 
100,000 women aged 20–69 years in 2000; this was statistically no different from the 1.5 
per 100,000 in 1999 (Tables 10 and 11, pages 49 and 50). However, the decrease between 
1995 and 2000 age-standardised incidence rates is statistically significant. 
• The highest detection rates for micro-invasive squamous cell cancer were for women in 
the 30–34 to 45–49 age groups.  
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Indicator 5.2: Incidence of squamous, 
adenocarcinoma, adeno-squamous and other 
cervical cancers 
Incidence rates of squamous, adenocarcinoma, adeno-squamous and other cervical cancer 
per 100,000 estimated resident female population in a 12-month period by 5-year age 
groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79,  
80–84, 85+) and for the target age group (20–69 years, age-standardised). 
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 Refer to Table 13 (page 52). 
 
Notes  
 1. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
 2. Rates for all ages are based on data for women aged 0–85+ years. 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 10: Age-standardised incidence rates of squamous, adenocarcinoma,  
adeno-squamous and other cervical cancer, Australia, 1989–2000 
 
 
Age 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
 (Number per 100,000 women) 
All ages 0–85+ years 13.5 13.3 13.3 12.2 11.9 12.9 10.7 10.3 8.6 9.0 8.2 7.6
20–69 years 18.0 17.7 17.2 16.0 15.8 16.9 13.8 13.4 11.2 11.6 10.9 9.5
• In 2000, there were 745 new cases of all cervical cancer (squamous, adenocarcinoma, 
adeno-squamous and other cervical cancer) diagnosed in Australia compared with the 
peak of 1,131 new cases in 1994. Of the 745 new cases, 578 were women in the target age 
group 20–69 years (Table 12, page 51). All but two cases of the remaining 167 were in 
women aged 70 years and over. 
• The age-standardised incidence rate of all cervical cancers declined to 7.6 per 100,000 
women for all women in Australia in 2000, and to 9.5 per 100,000 women in the target 
group. Between 1989 and 2000 the decline over all ages was 43.7%, and in the target age 
group was 47.2% (Table 13, page 52). 
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 Refer to Table 13 (page 52). 
 Note: Rates are expressed per 100,000 women. 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 11: Age-specific incidence rates of cervical cancer, Australia, 1999 and 2000 
 
 
 Age group 
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69
 (Number per 100,000 women) 
1999 1.2 7.5 10.4 13.5 14.6 11.4 11.0 10.8 16.4 15.6 10.9
2000 1.1 5.5 11.6 9.0 10.8 10.7 9.3 12.0 15.9 14.8 9.5
 
• The age-specific rate of cervical cancer incidence was highest in the 60–64 and 65–69 age 
groups in 1999 and 2000. It was lower in 2000 than in 1999 in all 5-year age groups for 
women aged 20–69 years, except in the 30–34 and 55–59 age groups. 
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 Refer to Tables 14b and 15b (pages 54 and 56). 
 Notes 
 1. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
 2. Bars on graphs represent 95% confidence intervals. 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 12: Age-standardised cervical cancer incidence rates by women aged  
20–69 years, states and territories, 1996–1999 and 1997–2000 
 
 
 NSW Vic Qld WA SA Tas ACT NT Australia
1996–1999 12.0 10.7 13.9 10.9 9.3 14.0 9.4 20.3 11.7
95% CI 11.2–12.8 9.9–11.6 12.8–15.1 9.6–12.4 8.0–10.8 11.1–17.3 6.5–13.1 14.2–28.1 11.3–12.2
1997–2000 11.3 9.4 12.7 9.9 9.3 13.0 8.8 14.7 10.8
95% CI 10.6–12.1 8.6–10.2 11.7–13.9 8.7–11.3 8.0–10.8 10.2–16.2 6.1–12.3 9.6–21.3 10.4–11.2
 
• In the period 1997–2000, the Australian Capital Territory had the lowest incidence at 8.8 
new cases per 100,000 women and the Northern Territory had the highest rate of 14.7 per 
100,000 women. Queensland (12.7) was significantly above the national average (10.8) 
and Victoria (9.4) was significantly below.  
• The age-standardised incidence rate declined in all states and territories between the two 
periods 1996–1999 and 1997–2000 except in South Australia where the rate did not 
change (Tables 14b and 15b, pages 54 and 56.) 
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 Refer to Table 16b (page 57). 
 Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 13: Age-standardised incidence rates of cervical cancer by histological type, 
women aged 20–69 years, Australia, 1989–2000 
 
 
Histological type 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Squamous 13.7 12.6 12.5 11.5 11.2 11.5 9.8 9.4 7.8 8.2 7.8 6.6
Adenocarcinoma 2.3 2.9 2.8 2.7 2.6 3.5 2.6 2.6 2.2 2.4 2.1 1.9
Adeno-squamous 0.9 1.0 0.8 1.0 0.9 0.7 0.6 0.7 0.6 0.5 0.4 0.5
Other 1.1 1.3 1.1 0.8 1.1 1.1 0.8 0.7 0.6 0.5 0.6 0.5
 
• In 2001, squamous cell carcinomas of the cervix accounted for 69.2% of all new cases of 
cervical cancer in women aged 20–69 years, adenocarcinomas 20.3%, adeno-squamous 
5.2%, and the remaining 5.2% comprised a range of other mixed and unknown 
histologies (Table 16a, page 57). 
• The trend from 1989 to 2000 for all histological types has been a decrease in the age-
standardised rates of cervical cancer per 100,000 in women aged 20–69 years. However, 
this trend is not statistically significant for adeno-squamous and adenocarcinoma. 
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Indicator 5.3: Incidence by location 
Incidence rates of cervical cancer per 100,000 estimated resident female population in a  
4-year period by location by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49,  
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 
years, age-standardised). 
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 Refer to Table 19 (page 60). 
 Notes 
 1. The age-standardised rates are presented as 4-year rolling blocks of data.  
 2. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
 3. Bars on graphs represent 95% confidence intervals. 
 4. The ASGC classification of remoteness has been used in this report; previous reports used RRMA  
 (see page 2). 
 Source: National Cancer Statistics Clearing House (AIHW). 
 Figure 14: Age-standardised incidence rates of cervical cancer by location by  
women aged 20–69 years, Australia, 1993–1996 and 1997–2000 
 
 
 Metropolitan  Regional  Remote 
 1993–1996 1997–2000 1993–1996 1997–2000 1993–1996 1997–2000 
AS rate 14.6 10.6 14.4 10.4 23.1 13.4 
95% CI 13.9–15.2 10.1–11.1 13.5–15.4 9.7–11.2 18.9–27.7 10.5–16.9 
 
• There were 2,127 new cases (67.7% of all new cases) of cervical cancer in major cities in 
the 4-year period 1997–2000, 933 new cases (29.7% of all new cases) in regional locations 
and 83 new cases (2.6% of all new cases) in remote locations (Table 18, page 59).  
• Age-standardised cervical cancer incidence rates in the period 1997–2000, for women in 
the target age group 20–69 years, were higher in remote locations (13.4 per 100,000 
women) than in regional locations (10.4) and major cities (10.6). This difference was not 
statistically significant (Table 19, page 60). 
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Mortality 
Cancer of the cervix is one of the few cancers for which there is an efficacious screening test 
for detection of precursors of the disease. Most deaths due to cervical cancer are potentially 
avoidable (Marcus & Crane 1998). The objective of the National Cervical Screening Program 
is to reduce this mortality rate. 
The three mortality indicators are mortality (by age and state), mortality by location 
(metropolitan, rural and remote), and Indigenous mortality (Indigenous and non-
Indigenous). These indicators measure the level of mortality from cervical cancer in the total 
female population by age and other demographic characteristics. The mortality indicators are 
important because from them an assessment can be made of changes in mortality in different 
age groups and particular target groups over time. However, note that changes in the 
mortality rates may not be evident for a number of years following an improvement in the 
participation rate. Therefore, the effectiveness of this measure needs to be viewed in the 
longer rather than the shorter term.  
Data issues 
• Two major changes that have occurred in the classification and processing of Australian 
mortality data require some caution when interpreting mortality data over time. They 
are: 
1. the introduction of the tenth revision of the International Classification of Diseases 
(ICD-10) for classifying deaths registered from 1 January 1999; and 
2. the introduction by the Australian Bureau of Statistics (ABS) of the Automated 
Coding System (ACS) for processing deaths registered from 1 January 1997. 
• As a result of this there is now a break in the mortality data series. In order to make 
mortality data coded using ICD-9 and ICD-10 comparable, the ABS has derived 
comparability factors to adjust data based on ICD-9. These comparability factors are 
derived from the movements in the underlying causes of death coded in ICD-9 compared 
with ICD-10 (ABS 2000). 
• For cervical cancer deaths, the comparability factor is 0.98, and the pre-1997 mortality 
data presented in this report have been adjusted accordingly. The effect of this is that the 
pre-1997 number of deaths appearing in this report is different from figures in previous 
Cervical Screening in Australia reports. 
• Prior to 1998, only South Australia, Western Australia and the Northern Territory had a 
relatively high coverage of Indigenous status identification in the deaths data. In 1998 
Queensland’s coverage of Indigenous deaths reached an acceptable level following the 
introduction of a new Death Information Form in 1996–97 which included a question on 
Indigenous status (ABS 1999). Therefore, in this report, cervical cancer deaths for 
Indigenous Australians include data from Queensland, South Australia, Western 
Australia and the Northern Territory. 
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Indicator 6.1: Mortality 
Death rate from cervical cancer per 100,000 estimated resident female population in a  
12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,  
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years,  
age-standardised). 
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  Refer to Table 21 (page 62).  
  Notes 
  1. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
  2. Deaths were derived by year of registration. 
  3. Rates for all ages are based on data for women aged 0–85+ years. 
  Source: AIHW Mortality Database. 
  Figure 15: Age-standardised death rates from cervical cancer, Australia, 1982–2002 
 
 
 ’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01 ’02
All ages 
0–85+ years 5.1 4.9 4.7 5.0 4.7 4.4 4.5 4.5 4.2 4.0 3.8 3.6 3.8 3.7 3.2 3.1 2.7 2.2 2.6 2.5 2.1
Target age 
20–69 years 5.4 5.4 4.9 5.0 5.2 4.4 4.6 4.6 4.8 4.0 3.5 3.8 4.1 3.8 3.0 3.0 2.7 2.1 2.6 2.5 2.1
 
• Cervical cancer was the 18th most common cause of cancer deaths in Australian women 
in 2002, accounting for 227 deaths.  
• The age-standardised death rate for women of all ages fell to 2.1 per 100,000 women in 
2002, much lower than the pre-screening program peaks of 5.1 per 100,000 in 1982 and  
5.0 per 100,000 in 1985.
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 Notes 
 1. Rates are expressed per 100,000 women. 
 2. Deaths were derived by year of registration. 
 Source: AIHW Mortality Database. 
 Figure 16: Age-specific cervical cancer death rates by age group, Australia, 1989–1992  
and 1999–2002 
 
 
 Age group 
 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
1989–1992 0.2 0.8 2.2 3.4 4.2 6.2 4.8 6.4 9.0 11.3 14.0 14.0 15.5 23.2
1999–2002 0.2 0.3 1.1 1.3 2.2 3.3 3.5 3.5 5.2 6.1 8.5 9.3 12.2 13.6
 
• Mortality from cervical cancer between the 1989–1992 and 1999–2002 periods declined in 
all age groups except for the age group 20–24 years where there was no difference. 
• In both 1989–1992 and 1999–2002 the age-specific rates of cervical cancer mortality 
increased with increasing age.  
 
 31 
 
 
 
NSW Vic Qld WA SA Tas ACT NT
0
2
4
6
8
10
12
14
16
18
20
Deaths per 100,000 women
1995–1998
1999–2002
 
 Refer to Tables 23 and 25 (pages 64 and 66). 
 Notes 
 1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the  
 smaller states and territories.  
 2. Deaths derived by year of registration. 
 3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population.  
 4. Bars on graphs represent 95% confidence intervals. 
 Source: AIHW Mortality Database. 
 Figure 17: Age-standardised cervical cancer death rates by women aged  
20–69 years, states and territories, 1995–1998 and 1999–2002 
 
 
 NSW Vic Qld WA SA Tas ACT NT Australia
Rate 1995–1998 3.4 2.6 3.1 3.5 2.0 5.1 4.4 8.6 3.1
95% CI 3.0–3.8 2.2–3.0 2.6–3.7 2.7–4.4 1.4–2.8 3.4–7.2 2.4–7.1 3.8–15.4 2.9–3.4
Rate 1999–2002 2.3 1.6 2.7 2.8 2.4 3.1 2.6 5.5 2.3
95% CI 2.0–2.6 1.3–2.0 2.3–3.3 2.1–3.5 1.7–3.1 1.8–4.8 1.2–4.9 2.5–10.2 2.1–2.5
 
• In the 4-year period 1999–2002 there were 976 deaths from cervical cancer in all states 
and territories compared with 1,183 in 1995–1998. 
• Age-standardised mortality varied from 1.6 deaths per 100,000 women in Victoria to 5.5 
per 100,000 in the Northern Territory in the 1999–2002 period.  
• The age-standardised death rates decreased in all jurisdictions between the two periods 
except in South Australia. The declines were significant in New South Wales and 
Victoria. Although the Northern Territory rate decreased sharply between the two 
periods, the rates are based on very small numbers and are subject to considerable 
variation. 
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Indicator 6.2: Mortality by location 
Death rate from cervical cancer per 100,000 estimated resident female population in a  
4-year period by location and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 
years, age-standardised). 
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 Refer to Table 27 (page 68). 
 Notes 
 1. Age-standardised rates are presented as 4-year rolling blocks of data.  
 2. Deaths were derived from place of usual residence and by year of registration.  
 3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population.  
 4. Bars on graphs represent 95% confidence intervals. 
 5. The ASGC classification of remoteness has been used in this report; previous reports used RRMA (see page 2). 
 Source: AIHW Mortality Database. 
 Figure 18: Age-standardised cervical cancer death rates by location, women aged  
20–69 years, 1995–1998 and 1999–2002 
 
 
 Major cities  Regional  Remote 
 1995–1998 1999–2002 1995–1998 1999–2002 1995–1998 1999–2002
Rate 2.9 2.2 3.3 2.5 6.0 3.0
95% CI 2.6–3.2 2.0–2.4 2.9–3.8 2.1–2.9 3.9–8.7 1.7–4.9
 
• During the 4-year period 1999–2002, there were 621 deaths (64% of all cervical cancer 
deaths in that period) in major cities, 321 deaths (33% of all cervical cancer deaths) in 
regional areas and 26 deaths (3% of all cervical cancer deaths) in remote areas (Table 26, 
page 67).  
• The age-standardised death rate for women in the target age group 20–69 years increased 
from major cities to rural areas and from rural to remote areas, though these differences 
were not statistically significant. 
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• In all three regions the age-standardised mortality rates declined between the periods 
1995–1998 and 1999–2002; however, only the decline in the metropolitan area was 
statistically significant. The largest overall mortality reduction was in remote areas (a 
mortality reduction of 50% between 1995–1998 and 1999–2002), but these rates are based 
on small numbers and therefore the decline is not statistically significant.  
Age-specific features 
(Tables 26 and 27, pages 67 and 68) 
• In major cities the death rates from cervical cancer increased with age. In regional and 
remote locations, although there is a general trend of rising death rates with age, the 
specific pattern is less clear because of the small numbers involved in calculating the 
rates. 
• In major cities, cervical cancer mortality decreased in all age groups between the periods 
1995–1998 and 1999–2002. In regional locations, mortality declined in most age groups. 
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Indicator 6.3: Indigenous mortality 
Death rate from cervical cancer per 100,000 estimated resident female population in a  
4-year period by Indigenous status and 5-year age groups (20–24, 25–29, 30–34, 35–39,  
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75+) and for the target age group (20–69 
years, age-standardised). 
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 Rrefer to Table 28, page 69. 
 Notes 
 1. Age-standardised rates are presented as 4-year rolling blocks of data.  
 2. Deaths were derived by year of registration.  
 3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population.  
 4. Only Queensland, South Australia, Western Australia and the Northern Territory have Indigenous death  
 registration data considered to be of a publishable standard. 
 5. Bars on graphs represent 95% confidence intervals. 
 Source: AIHW Mortality Database. 
 Figure 19: Age-standardised cervical cancer mortality rates by Indigenous status, 
women aged 20–69 years (Queensland, Western Australia, South Australia and  
Northern Territory), 1999–2002 
 
 
  Indigenous  Non-Indigenous
AS rate (A)  14.9 2.5
95% CI  9.1–22.6 2.2–2.8
 
• Due to the difficulties of Indigenous identification in mortality data, only data from 
Queensland, Western Australia, South Australia and the Northern Territory are 
considered to be of publishable standard. Therefore, all cervical cancer mortality data for 
both Indigenous women and non-Indigenous women used in this analysis are confined 
to these jurisdictions. 
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• The age-standardised mortality rate attributable to cervical cancer among Indigenous 
women in the target age group in 1999–2002 was 14.9 per 100,000 women and was 
considerably higher than the mortality rate for non-Indigenous women in the same age 
range (2.5 per 100,000 women) (Table 28, page 69). 
• Compared with non-Indigenous women, Indigenous women experienced high rates of 
mortality in every age group (Table 28, page 69). 
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Tables 
Indicator 1: Participation  
Table 1a: Number of women participating in the National Cervical Screening Program by age, 
states and territories, 2000–2001 
Age group NSW Vic(a) Qld WA(a) SA(b) Tas ACT(a) NT Australia
20–24 98,410 81,673 62,480 33,698 25,410 8,804 6,193 4,595 321,263
25–29 143,840 114,693 79,515 43,183 32,306 10,127 7,845 5,898 437,407
30–34 153,836 125,139 81,104 46,448 36,257 10,994 8,158 5,827 467,763
35–39 154,920 121,537 80,964 47,090 37,436 11,924 7,976 5,043 466,890
40–44 140,924 112,399 74,268 43,390 35,941 11,193 7,474 4,188 429,777
45–49 118,907 95,793 62,383 36,619 30,829 9,475 6,708 3,464 364,178
50–54 99,838 82,150 52,047 29,221 26,386 8,081 6,059 2,509 306,291
55–59 68,905 56,506 35,118 18,729 18,311 5,505 3,665 1,375 208,114
60–64 50,567 42,868 24,336 14,060 14,155 4,106 2,378 766 153,236
65–69 35,430 31,124 16,749 9,621 10,236 2,974 1,519 359 108,012
70–74 14,641 10,486 8,042 3,641 6,495 798 483 149 44,735
75–79 5,341 3,617 3,098 1,173 n.a. 327 168 53 13,777
80+ 2,190 1,584 1,354 542 n.a. 133 46 26 5,875
Not stated 3,720 0 320 0 20 3 9 18 4,090
All ages  
20–80+ years 1,091,469 879,569 581,778 327,415 273,782 84,444 58,681 34,270 3,331,408
Target age 
20–69 years 1,065,577 863,882 568,964 322,059 267,267 83,183 57,975 34,024 3,262,931
(a) The Victorian, Western Australian and Australian Capital Territory registers only register women with a Victorian, Western Australian or  
 Australian Capital Territory address respectively. 
(b) South Australia has grouped women aged 70 years or more, and for the purpose of this table, they appear in the 70–74 age group. 
Note: These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women 
resident overseas; however, the likely impact of double counting is probably very small. 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
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Table 1b: Proportion of women participating in the National Cervical Screening Program by age, 
states and territories, 2000–2001 
Age group NSW Vic(a) Qld WA(a) SA Tas ACT(a) NT Australia 
 (Per cent) 
20–24 46.4 51.1 51.0 53.0 54.8 62.7 47.8 59.9 50.3 
25–29 58.8 63.3 59.3 62.7 64.2 66.9 59.5 64.2 61.0 
30–34 63.7 67.2 61.2 65.9 68.6 68.5 64.9 65.9 64.9 
35–39 63.7 67.6 60.5 66.1 68.3 69.8 64.9 64.1 64.8 
40–44 62.9 68.0 59.9 64.8 68.5 67.5 64.6 63.1 64.4 
45–49 63.7 69.3 60.0 64.3 68.9 67.6 66.0 64.9 65.0 
50–54 61.7 68.1 57.1 61.7 65.8 65.8 68.5 61.9 63.0 
55–59 63.2 71.2 58.3 62.7 69.0 66.1 72.1 62.3 64.9 
60–64 52.9 61.1 48.8 54.9 60.7 55.2 63.2 55.5 55.3 
65–69 43.7 52.3 41.9 46.5 51.2 48.1 54.4 42.6 46.7 
70–74 18.1 17.7 20.8 18.9 31.3 13.4 19.0 24.7 19.7 
75–79 7.6 7.1 9.4 7.3 0.0 6.2 7.6 13.6 7.0 
80+ 2.4 2.4 3.1 2.5 0.0 1.9 1.8 5.5 2.3 
All ages 20–80+ years         
Crude rate 53.5 58.0 52.6 56.6 57.5 58.1 58.4 61.8 55.3 
AS rate 53.0 57.7 51.3 55.0 58.2 58.0 56.2 55.9 54.7 
95% CI 52.9–53.1 57.6–57.9 51.2–51.4 54.8–55.1 58.0–58.4 57.6–58.3 55.8–56.7 55.2–56.6 54.6–54.7 
Target age 20–69 years  
Crude rate 59.2 64.5 57.4 61.7 64.9 65.4 62.2 63.0 61.1 
AS rate 59.1 64.6 57.0 61.4 64.9 65.2 62.8 61.7 61.0 
95% CI 59.0–59.3 64.5–64.8 56.8–57.1 61.2–61.6 64.6–65.1 64.7–65.6 62.3–63.4 61.0–62.4 60.9–61.1 
(a) The Victorian, Western Australian and Australian Capital Territory registers only register women with a Victorian, Western Australian or  
 Australian Capital Territory address respectively. 
Notes 
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
2. Rates are standardised to the 2001 Australian total population. 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
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Table 2a: Number of women participating in the National Cervical Screening Program by age, 
states and territory, 2001–2002 
Age group NSW Vic(a) Qld WA SA Tas ACT(a) Australia 
20–24 99,958 83,123 61,476 33,910 25,410 8,697 6,521 319,095 
25–29 139,111 110,646 75,345 41,288 30,743 9,517 7,710 414,360 
30–34 156,878 127,812 81,561 46,471 36,394 11,037 8,296 468,449 
35–39 152,364 121,345 79,222 45,781 36,643 11,353 7,980 454,688 
40–44 144,459 114,935 75,625 43,631 36,315 11,304 7,582 433,851 
45–49 121,346 98,330 63,458 37,083 31,474 9,552 6,746 367,989 
50–54 101,738 83,979 53,402 30,153 26,856 8,156 6,048 310,332 
55–59 74,048 60,692 38,083 19,973 20,004 5,853 4,028 222,681 
60–64 52,909 44,356 25,943 14,410 14,611 4,307 2,529 159,065 
65–69 37,174 31,840 17,759 9,880 10,729 3,069 1,613 112,064 
70–74 14,522 10,825 8,446 3,595 4,108 849 474 42,819 
75–79 5,165 3,851 3,115 1,123 1,642 307 152 15,355 
80+ 2,183 1,721 1,406 506 660 138 46 6,660 
Not stated 3,366 0 207 0 21 7 4 3,605 
All ages 
20–80+ years 1,105,221 893,455 585,048 327,804 275,610 84,146 59,729 3,331,013 
Target age 
20–69 years 1,079,985 877,058 571,874 322,580 269,179 82,845 59,053 3,262,574 
(a) The Victorian and Australian Capital Territory registers only register women with a Victorian or Australian Capital Territory address respectively. 
Notes 
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
2. Northern Territory data were not available for 2002. 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
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Table 2b: Proportion of women participating in the National Cervical Screening Program by age, 
states and territory, 2001–2002 
Age group NSW Vic(a) Qld WA SA Tas ACT(a) Australia 
 (Per cent) 
20–24 46.7 51.1 49.5 52.6 54.4 61.9 49.3 49.9 
25–29 58.4 62.9 57.5 61.6 63.6 66.3 59.8 60.2 
30–34 63.0 66.9 59.5 64.6 68.4 68.5 64.5 64.1 
35–39 63.5 67.8 59.3 64.7 68.3 68.8 65.8 64.4 
40–44 63.1 68.2 59.1 64.1 68.5 67.4 65.0 64.3 
45–49 64.3 70.2 59.8 64.0 69.9 67.5 66.7 65.4 
50–54 61.8 68.4 57.0 61.5 66.2 65.5 67.1 63.0 
55–59 64.2 72.1 58.7 62.7 70.7 66.3 73.2 65.7 
60–64 54.2 62.0 49.6 54.1 61.6 56.3 64.2 56.1 
65–69 45.4 52.9 43.3 46.5 53.5 49.2 55.4 48.0 
70–74 18.0 18.4 21.6 18.5 20.1 14.2 18.7 18.9 
75–79 7.3 7.4 9.3 6.9 8.7 5.8 6.7 7.7 
80+ 2.3 2.4 3.1 2.2 2.5 1.9 1.7 2.5 
All ages 20–80+ years        
Crude rate 53.5 58.1 51.8 55.8 57.7 57.7 58.6 55.1 
AS rate 53.2 58.0 50.7 54.3 58.4 57.8 56.6 54.6 
95% CI 53.1–53.3 57.9–58.1 50.6–50.9 54.1–54.5 58.2–58.7 57.4–58.2 56.1–57.0 54.5–54.7 
Target age 20–69 years    
Crude rate 59.4 64.7 56.5 61.0 65.3 65.2 62.6 61.0 
AS rate 59.4 64.9 56.3 60.7 65.2 65.0 63.3 61.0 
95% CI 59.3–59.5 64.7–65.0 56.1–56.4 60.5–60.9 65.0–65.5 64.5–65.4 62.8–63.8 60.9–61.0 
(a) The Victorian and Australian Capital Territory registers only register women with a Victorian or Australian Capital Territory address respectively. 
Notes 
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
2. Rates are standardised to the 2001 Australian total population. 
3. Northern Territory data were not available for 2002 so all Australia rates in the table exclude the Northern Territory. 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
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 Indicator 2: Early re-screening 
Table 3: Number of women with repeat screenings in the 21 months following a negative Pap 
smear in February 2001, states and territory, and Australia 2000–2001 and 2001–2002 
 
No. of tests 
 
NSW 
 
Vic(a) 
 
Qld WA(b) SA Tas ACT(a) 
Australia 
2000–2001 
Australia
2001–2002 
 Number of women 
0 38,571 33,610 21,578 11,440 10,103 2,790 2,246 114,902 120,338 
1 14,276 13,557 7,049 3,991 2,711 912 713 46,105 43,209 
2 1,595 1,768 954 423 308 95 104 6,075 5,247 
3 251 482 209 67 41 21 14 1,199 1,085 
4 48 94 44 6 7 1 5 251 205 
5 or more 14 38 5 0 4 0 0 108 61 
(a) The Victorian and Australian Capital Territory registries only register women with a Victorian or Australian Capital Territory address 
respectively.  
(b) In 2000–2001 Western Australia only provided data for women with a Western Australian address. 
Notes 
1. Northern Territory data were unavailable for 2001 and 2002. 
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty 
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women 
resident overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
Table 4: Percentage of women with repeat screenings in the 21 months following a negative Pap 
smear in February 2001, states and territory, and Australia 2000–2001 and 2001–2002 
 
No. of tests 
 
NSW 
 
Vic(a) 
 
Qld WA(b) SA Tas ACT(a) 
Australia 
2000–2001 
Australia
2001–2002 
 Percentage 
0 70.4 67.8 72.3 71.8 76.7 73.1 72.9 68.1 70.7 
1 26.1 27.4 23.6 25.1 20.6 23.9 23.1 27.3 25.4 
2 2.9 3.6 3.2 2.7 2.3 2.5 3.4 3.6 3.1 
3 0.5 1.0 0.7 0.4 0.3 0.6 0.5 0.7 0.6 
4 0.1 0.2 0.1 0.0 0.1 0.0 0.2 0.1 0.1 
5 or more 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 
(a) The Victorian and Australian Capital Territory registries only register women with a Victorian or Australian Capital Territory address 
respectively.  
(b) In 2000–2001 Western Australia only provided data for women with a Western Australian address. 
Notes 
1. Northern Territory data were unavailable for 2001 and 2002. All Australia rates exclude the Northern Territory. 
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty 
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women 
resident overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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Indicator 3: Low-grade abnormality detection 
Table 5a: Number of low- and high-grade abnormalities on histology for women aged 20–69 years, 
states and territory, 2001  
Abnormalities NSW Vic Qld WA SA Tas ACT Australia 
Low-grade 6,416 3,099 4,086 2,308 1,335 591 291 18,126 
High-grade 4,614 2,855 2,890 1,515 961 471 249 13,555 
Ratio 1.39 1.09 1.41 1.52 1.39 1.25 1.17 1.34 
 As a percentage of all screens in 2001 
Low-grade 1.0 0.6 1.3 1.2 0.9 1.2 0.9 1.0 
High-grade 0.8 0.6 0.9 0.8 0.7 1.0 0.8 0.7 
Notes 
1. Northern Territory data were unavailable for 2001. 
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty 
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women 
resident overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
 
 
 
Table 5b: Number of low- and high-grade abnormalities on histology for women aged 20–69 years, 
states and territory, 2002 
Abnormalities NSW Vic Qld WA SA Tas ACT Australia 
Low-grade 6,477 3,015 4,273 2,661 1,205 473 332 18,436 
High-grade 5,034 3,301 3,056 1,647 952 417 253 14,660 
Ratio 1.29 0.91 1.40 1.62 1.27 1.13 1.31 1.26 
 As a percentage of all screens in 2002 
Low-grade 1.1 0.6 1.3 1.4 0.8 1.1 1.0 1.0 
High-grade 0.8 0.7 1.0 0.9 0.6 0.9 0.8 0.8 
Notes 
1. Northern Territory data were unavailable for 2001–2002. 
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty 
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women 
resident overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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Indicator 4: High-grade abnormality detection 
Table 6a: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened, 
states and territory, 2001 
Age group NSW Vic Qld WA SA(a) Tas ACT Australia 
20–24 18.2 12.6 18.9 17.8 13.7 23.7 2.2 16.3 
25–29 16.5 12.7 18.0 17.6 13.3 20.4 13.0 15.6 
30–34 10.4 8.1 12.1 11.0 9.4 11.8 11.1 10.1 
35–39 6.2 5.2 8.1 7.2 6.4 10.0 11.3 6.6 
40–44 4.2 3.5 5.1 4.8 3.9 7.0 9.9 4.4 
45–49 3.1 2.0 3.7 3.2 3.6 4.9 5.3 3.0 
50–54 1.7 1.3 2.7 1.5 2.2 1.3 1.7 1.8 
55–59 1.4 0.9 2.4 1.4 1.5 2.1 2.8 1.5 
60–64 1.6 0.9 2.1 1.0 2.2 2.9 3.0 1.5 
65–69 1.6 1.2 2.2 1.6 1.8 2.3 4.7 1.6 
70–74 1.2 1.4 1.7 3.0 4.8 4.4 11.7 2.1 
75–79 3.7 3.9 6.0 1.2 n.a. 0.0 0.0 3.9 
80–84 3.4 1.6 10.6 3.6 n.a. 17.9 0.0 4.9 
85+ 6.1 0.0 0.0 7.9 n.a. 0.0 0.0 3.2 
All ages 
20–85+ years 
 
7.4 
 
5.6 8.9 7.9 6.5 
 
9.8 
 
7.6 7.2 
Target age 
20–69 years 7.5 5.7 9.0 8.0 6.5 9.8 7.6 7.3 
 (a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group. 
Notes   
1. Northern Territory data were unavailable for 2001. All Australia rates exclude the Northern Territory. 
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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Table 6b: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened by 
age, states and territory, 2002 
Age group NSW Vic Qld WA SA Tas ACT Australia 
20–24 21.0 17.2 19.7 18.4 13.5 24.0 15.8 18.8 
25–29 18.0 14.5 17.4 18.8 14.9 15.4 13.3 16.6 
30–34 11.2 9.5 14.4 12.0 9.7 13.6 12.5 11.3 
35–39 7.5 5.4 7.8 7.5 6.2 9.4 6.8 6.9 
40–44 4.9 4.0 6.0 4.8 3.4 7.3 4.9 4.8 
45–49 3.0 2.1 4.5 2.9 2.9 2.9 1.8 3.0 
50–54 1.9 1.3 2.6 2.7 1.6 3.5 2.7 2.0 
55–59 1.6 1.1 2.6 1.7 1.7 2.1 2.6 1.7 
60–64 1.2 0.8 2.2 1.6 1.2 0.9 1.4 1.3 
65–69 1.1 1.0 2.4 0.9 1.4 1.8 4.5 1.4 
70–74 2.4 2.1 3.3 2.5 3.1 8.4 4.0 2.7 
75–79 1.8 0.9 3.0 0.0 10.2 0.0 0.0 2.5 
80–84 3.5 0.0 8.8 5.7 4.0 0.0 47.6 4.2 
85+ 3.5 0.0 30.6 11.6 55.6 0.0 0.0 13.5 
All ages 
20–85+ years 
8.1 6.5 9.4 8.4 6.3 9.2 7.6 7.8 
Target age 
20–69 years 8.2 6.6 9.5 8.5 6.3 9.3 7.6 7.9 
Notes   
1. Northern Territory data were unavailable for 2002. All Australia rates exclude the Northern Territory. 
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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Table 7a: Number of histologically confirmed high-grade abnormalities by age, states and  
territory, 2001 
Age group NSW Vic Qld WA SA(a) Tas ACT Australia 
20–24 1,008 588 652 343 194 116 8 2,909 
25–29 1,334 821 786 429 232 116 57 3,775 
30–34 929 600 558 297 189 75 51 2,699 
35–39 544 366 365 193 130 68 51 1,717 
40–44 343 232 218 122 78 45 42 1,080 
45–49 216 110 130 70 62 27 20 635 
50–54 102 63 82 27 33 6 6 319 
55–59 58 32 49 16 16 7 6 184 
60–64 48 22 29 9 17 7 4 136 
65–69 32 21 21 9 10 4 4 101 
70–74 10 8 8 7 16 2 3 54 
75–79 11 8 10 1 0 0 0 30 
80–84 3 1 6 1 0 1 0 12 
85+ 2 0 0 1 0 0 0 3 
Age not 
stated 0 0 1 0 0 0 0 1 
All ages  
20–85+ years 
 
4,640 
 
2,872 2,915 1,525 977 
 
474 
 
252 13,655 
Target age 
20–69 years 4,614 2,855 2,890 1,515 961 471 249 13,555 
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group. 
Notes   
1. Northern Territory data were unavailable for 2001. 
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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Table 7b: Number of histologically confirmed high-grade abnormalities by age, states and  
territory, 2002 
Age group NSW Vic Qld WA SA Tas ACT Australia 
20–24 1,152 806 680 358 192 113 58 3,359 
25–29 1,378 894 760 434 254 78 57 3,855 
30–34 1,004 705 664 322 198 82 59 3,034 
35–39 640 375 352 194 127 56 30 1,774 
40–44 406 262 254 122 69 46 21 1,180 
45–49 211 122 161 62 51 15 7 629 
50–54 113 60 79 47 24 15 9 347 
55–59 72 38 53 20 19 7 6 215 
60–64 35 21 30 13 10 2 2 113 
65–69 23 18 23 5 8 3 4 84 
70–74 19 13 15 5 7 4 1 64 
75–79 5 2 5 0 9 0 0 21 
80–84 3 0 5 1 1 0 1 11 
85+ 1 0 6 1 5 0 0 13 
Age not 
stated 0 0 1 0 0 0 0 1 
All ages  
20–85+ years 
 
5,062 
 
3,316 3,088 1,584 974 
 
421 
 
255 14,700 
Target age 
20–69 years 5,034 3,301 3,056 1,577 952 417 253 14,590 
Notes   
1. Northern Territory data were unavailable for 2001–2002. 
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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Table 8a: Number of women screened by age, states and territory, 2001 
Age group NSW Vic Qld WA SA(a) Tas ACT Australia 
20–24 55,327 46,511 34,551 19,292 14,136 4,892 3,558 178,267 
25–29 81,027 64,645 43,714 24,378 17,509 5,700 4,380 241,353 
30–34 89,191 73,696 46,004 27,016 20,161 6,369 4,601 267,038 
35–39 88,177 69,967 45,033 26,936 20,314 6,779 4,522 261,728 
40–44 81,892 66,241 42,340 25,501 20,004 6,412 4,250 246,640 
45–49 69,104 56,362 35,401 21,883 17,098 5,521 3,794 209,163 
50–54 58,595 48,786 29,858 18,232 14,698 4,783 3,473 178,425 
55–59 40,658 33,830 20,348 11,590 10,340 3,283 2,119 122,168 
60–64 29,437 24,988 13,923 8,580 7,669 2,418 1,336 88,351 
65–69 20,375 17,710 9,555 5,758 5,585 1,713 860 61,556 
70–74 8,283 5,923 4,572 2,321 3,344 452 257 25,152 
75–79 2,945 2,071 1,665 809 0 178 106 7,774 
80–84 890 626 566 278 0 56 19 2,435 
85+ 327 255 196 126 0 21 4 929 
Age not 
stated 
 
1,895 
 
0 147 0 8 
 
3 
 
5 2,058 
All ages 
20–85+ years 
 
628,123 
 
511,611 327,873 192,700 150,866 
 
48,580 
 
33,284 1,893,037 
Target age 
20–69 years 613,783 502,736 320,727 189,166 147,514 47,870 32,893 1,854,689 
 (a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group. 
Notes   
1. Northern Territory data were unavailable for 2001. 
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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Table 8b: Number of women screened by age, states and territory, 2002 
Age group NSW Vic Qld WA SA Tas ACT Australia 
20–24 54,880 46,923 34,551 19,450 14,198 4,715 3,676 178,393 
25–29 76,499 61,866 43,714 23,061 17,059 5,055 4,278 231,532 
30–34 89,887 74,403 46,004 26,730 20,357 6,046 4,727 268,154 
35–39 85,841 69,551 45,033 26,005 20,480 5,976 4,427 257,313 
40–44 83,130 65,928 42,340 25,315 20,270 6,269 4,288 247,540 
45–49 69,803 56,897 35,401 21,614 17,643 5,201 3,790 210,349 
50–54 58,172 47,711 29,858 17,274 14,825 4,336 3,280 175,456 
55–59 43,921 35,963 20,348 11,916 11,371 3,346 2,335 129,200 
60–64 30,177 25,118 13,923 8,079 8,053 2,343 1,447 89,140 
65–69 20,961 17,777 9,555 5,535 5,849 1,655 885 62,217 
70–74 7,840 6,280 4,572 1,977 2,242 478 250 23,639 
75–79 2,770 2,181 1,665 619 880 151 57 8,323 
80–84 866 705 566 176 248 51 21 2,633 
85+ 287 284 196 86 90 17 4 964 
Age not 
stated 
1,687 0 147 0 14 4 0 1,852 
All ages 
20–85+ years 
 
626,721 
 
511,587 327,873 187,837 153,579 
 
45,643 
 
33,465 1,886,705 
Target age 
20–69 years 613,271 502,137 320,727 184,979 150,105 44,942 33,133 1,849,294 
Notes   
1. Northern Territory data were unavailable for 2001. 
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
Source: State and territory Cervical Cytology Registry data. 
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 Table 9a: Age-standardised high-grade abnormality rate on histology per 1,000 women screened 
aged 20–69 years, states and territory, 2001 
 NSW Vic Qld WA SA Tas ACT Australia 
All ages 20–85+ years        
AS rate 6.6 4.9 7.8 6.9 6.1 8.9 6.7 6.4 
95% CI 6.4–6.9 4.7–5.2 7.4–8.1 6.4–7.4 5.8–6.5 7.8–10.1 5.7–7.7 6.3–6.6 
Target age 20–69 years    
AS rate 7.1 5.4 8.2 7.4 6.3 9.5 7.0 6.9 
95% CI 6.9–7.3 5.2–5.6 7.9–8.6 7.0–7.8 5.9–6.8 8.6–10.4 6.2–8.0 6.8–7.0 
Notes 
1. Northern Territory data were unavailable for 2001. All Australia rates exclude the Northern Territory. 
2. Rates are standardised to the 2001 Australian total population. 
3. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
 
 
Table 9b: Age-standardised high-grade abnormality rate on histology per 1,000 women screened 
aged 20–69 years, states and territory, 2002 
 NSW Vic Qld WA SA Tas ACT Australia 
All ages 20–85+ years        
AS rate 7.2 5.6 8.7 7.4 7.1 8.2 7.5 7.1 
95% CI 7.0–7.5 5.4–5.8 8.1–9.3 6.8–8.0 6.1–8.2 7.4–9.1 5.3–10.0 6.9–7.3 
Target age 20–69 years        
AS rate 7.9 6.3 8.7 7.9 6.2 8.9 7.1 7.5 
95% CI 7.7–8.1 6.1–6.5 8.4–9.0 7.5–8.3 5.8–6.6 8.1–9.8 6.3–8.1 7.4–7.6 
Notes 
1. Northern Territory data were unavailable for 2002. All Australia rates exclude the Northern Territory. 
2. Rates are standardised to the 2001 Australian total population. 
3. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of 
difficulty in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of 
women resident overseas; however, the likely impact of double counting is probably very small. 
Source: AIHW analysis of state and territory Cervical Cytology Registry data. 
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Indicator 5.1: Incidence of micro-invasive cervical cancer 
Table 10: New cases of micro-invasive cervical cancer by age, Australia, 1989–2000 
Age group 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
0–4 0 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0
15–19 0 0 1 0 0 0 0 1 0 0 0 0
20–24 1 4 0 5 1 7 1 6 3 2 2 1
25–29 13 14 14 14 9 17 16 17 10 18 14 12
30–34 28 32 31 32 32 36 42 18 27 18 14 25
35–39 10 25 40 25 26 30 29 35 21 26 20 14
40–44 17 26 30 24 17 24 30 23 21 22 15 7
45–49 6 18 9 13 15 26 23 12 11 15 7 15
50–54 4 6 11 12 17 9 12 11 8 13 7 5
55–59 5 8 7 11 5 5 9 7 8 3 8 4
60–64 7 8 7 8 7 10 11 6 5 5 2 3
65–69 2 6 7 9 10 6 7 10 2 2 3 0
70–74 0 2 4 2 3 6 5 3 4 3 2 0
75–79 1 3 3 2 1 3 5 2 2 2 1 1
80–84 1 0 2 0 0 0 1 1 0 2 0 2
85+ 0 0 0 0 1 2 1 1 0 0 0 0
All ages  
0–85+ years 
 
95 
 
152 
 
166 157 144 181 192 153
 
122 
 
131 
 
95 89
Target age 
20–69 years 93 147 156 153 139 170 180 145 116 124 92 86
Note: Cancer incidence estimates provided in this publication were made in February 2004. These estimates may be updated at any time as case 
details are added, modified or deleted in the national database. These modifications may occur several years after the initial diagnosis as 
additional case details are received by the state and territory cancer registries from data suppliers and then passed to the NCSCH. This may have 
the impact of making incidence estimates for the same year incompatible between publications, but for the most part these changes are very 
small. 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 11: Age-specific and age-standardised incidence rates of micro-invasive cervical cancer by 
age, Australia, 1989–2000 
Age group 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0
20–24 0.2 0.6 0.0 0.7 0.1 1.0 0.1 0.9 0.4 0.3 0.3 0.2
25–29 1.8 2.0 2.0 2.0 1.3 2.5 2.3 2.4 1.4 2.5 1.9 1.7
30–34 4.1 4.6 4.4 4.4 4.4 4.9 5.7 2.5 3.8 2.5 2.0 3.5
35–39 1.5 3.8 6.0 3.7 3.8 4.3 4.1 4.8 2.8 3.5 2.6 1.9
40–44 2.9 4.2 4.7 3.7 2.6 3.7 4.5 3.4 3.0 3.1 2.1 1.0
45–49 1.3 3.8 1.8 2.4 2.6 4.4 3.7 1.9 1.7 2.3 1.1 2.2
50–54 1.0 1.5 2.7 2.8 3.9 2.0 2.5 2.2 1.5 2.3 1.2 0.8
55–59 1.4 2.2 2.0 3.0 1.3 1.3 2.3 1.7 1.9 0.7 1.8 0.8
60–64 1.9 2.2 1.9 2.2 1.9 2.8 3.1 1.7 1.4 1.3 0.5 0.8
65–69 0.6 1.7 2.0 2.5 2.8 1.7 2.0 2.8 0.6 0.6 0.9 0.0
70–74 0.0 0.7 1.4 0.7 1.0 1.9 1.5 0.9 1.2 0.9 0.6 0.0
75–79 0.5 1.4 1.3 0.9 0.4 1.3 2.1 0.8 0.8 0.7 0.4 0.3
80–84 0.7 0.0 1.4 0.0 0.0 0.0 0.6 0.6 0.0 1.1 0.0 1.1
85+ 0.0 0.0 0.0 0.0 0.8 1.6 0.7 0.7 0.0 0.0 0.0 0.0
All ages 0–85+ years                       
Crude rate 1.1 1.8 1.9 1.8 1.6 2.0 2.1 1.7 1.3 1.4 1.0 0.9
AS rate (A) 1.2 1.8 2.0 1.8 1.7 2.0 2.1 1.7 1.3 1.4 1.0 0.9
95% CI 0.9–1.4 1.6–2.2 1.7–2.3 1.6–2.2 1.4–2.0 1.7–2.3 1.9–2.5 1.4–2.0 1.1–1.6 1.2–1.6 0.8–1.2 0.7–1.1
AS rate (W) 1.1 1.7 1.8 1.7 1.5 1.9 1.9 1.5 1.2 1.3 0.9 0.9
95% CI 0.9–1.3 1.4–2.0 1.5–2.1 1.4–2.0 1.3–1.8 1.6–2.1 1.7–2.2 1.3–1.8 1.0–1.4 1.1–1.5 0.7–1.1 0.7–1.1
Target age 20–69 years                       
Crude rate 1.8 2.8 2.9 2.8 2.5 3.0 3.2 2.5 2.0 2.1 1.5 1.4
AS rate (A) 1.8 2.8 2.9 2.8 2.6 3.0 3.2 2.5 2.0 2.1 1.5 1.4
95% CI 1.4–2.2 2.4–3.3 2.5–3.4 2.4–3.3 2.1–3.0 2.6–3.5 2.7–3.7 2.1–2.9 1.6–2.4 1.7–2.5 1.2–1.9 1.1–1.7
AS rate (W) 1.8 2.7 2.8 2.8 2.5 3.0 3.1 2.5 2.0 2.0 1.5 1.4
95% CI 1.4–2.2 2.3–3.2 2.4–3.3 2.3–3.2 2.1–2.9 2.5–3.4 2.7–3.6 2.1–2.9 1.6–2.3 1.7–2.4 1.2–1.8 1.1–1.7
Notes  
1. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
2. In 2001 the Australian Bureau of Statistics (ABS) carried out a full population census and a national health survey. These led to the revision of 
the ABS estimated resident population (ERP) data, the introduction of a new Australian standard population for use in age standardisation 
and the production of new estimates of hysterectomy status among Australian women. The denominators for participation rates presented in 
this report have been calculated using the 2001 ABS National Health Survey hysterectomy fractions and the revised ERP values and age-
adjusted using the 2001 Australian standard population. The denominators for the equivalent rates in previous reports were calculated using 
the 1995 ABS National Health Survey hysterectomy fractions and unrevised ERP values and age-adjusted using the 1991 Australian standard 
population. The combined effect of these changes is that participation rates presented in this report are on average between 1 and 2 
percentage points lower than equivalent rates in previous reports. 
Source: National Cancer Statistics Clearing House (AIHW). 
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Indicator 5.2: Incidence of invasive squamous, adenocarcinoma, 
adeno-squamous and other cervical cancer 
Table 12: New cases of cervical cancer by age, Australia, 1989–2000 
Age group 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
0–4 1 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 1 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0
15–19 1 1 1 0 1 1 2 1 1 2 0 2
20–24 16 12 12 9 10 16 4 15 10 10 8 7
25–29 67 59 49 53 37 49 52 43 44 48 55 40
30–34 130 113 120 107 105 124 112 68 78 84 74 83
35–39 122 156 140 126 129 131 110 141 99 102 102 68
40–44 128 139 150 132 128 131 118 117 102 101 104 79
45–49 94 120 104 101 101 131 99 102 79 110 76 72
50–54 82 70 90 77 89 87 58 80 74 65 66 58
55–59 83 80 63 78 79 73 69 64 51 52 49 57
60–64 85 78 81 76 76 88 71 61 52 56 63 63
65–69 100 76 89 88 91 94 78 65 57 55 54 51
70–74 67 66 79 72 63 78 71 59 45 61 46 57
75–79 51 51 48 53 46 65 50 51 45 44 42 50
80–84 28 29 35 34 37 40 30 41 32 39 33 37
85+ 18 23 33 22 21 22 33 25 28 29 21 21
All ages  
0–85+ years 
 
1,072 
 
1,073 
 
1,094 1,028 1,013 1,131 957 933
 
797 
 
858 
 
793 745
Target age 
20–69 years 
 
907 
 
903 
 
898 847 845 924 771 756
 
646 
 
683 
 
651 578
Notes  
1. The above table includes the incidence of micro-invasive and invasive cervical cancers. 
2. Cancer incidence estimates provided in this publication were made in February 2004. These estimates may be updated at any time as case 
details are added, modified or deleted in the national database. These modifications may occur several years after the initial diagnosis as 
additional case details are received by the state and territory cancer registries from data suppliers and then passed to the NCSCH. This may 
have the impact of making incidence estimates for the same year incompatible between publications, but for the most part these changes are 
very small. 
 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 13: Age-specific and age-standardised incidence rates of cervical cancer by age, Australia, 
1989–2000 
Age group 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.1 0.1 0.2 0.0 0.2 0.2 0.3 0.2 0.2 0.3 0.0 0.3
20–24 2.4 1.8 1.7 1.3 1.4 2.3 0.6 2.2 1.5 1.5 1.2 1.1
25–29 9.5 8.3 7.0 7.7 5.4 7.2 7.6 6.1 6.1 6.5 7.5 5.5
30–34 19.2 16.3 16.9 14.8 14.4 16.9 15.3 9.4 10.9 11.8 10.4 11.6
35–39 18.9 23.8 21.1 18.6 18.7 18.8 15.4 19.3 13.3 13.6 13.5 9.0
40–44 21.5 22.5 23.5 20.6 19.8 19.9 17.7 17.2 14.7 14.4 14.6 10.8
45–49 20.6 25.1 20.7 18.8 17.6 22.0 16.1 15.9 12.3 16.8 11.4 10.7
50–54 21.1 17.5 21.8 18.2 20.5 19.2 12.2 16.1 13.8 11.4 11.0 9.3
55–59 23.0 22.3 17.6 21.3 21.0 18.9 17.4 15.7 12.1 12.0 10.8 12.0
60–64 22.9 21.0 21.9 20.8 21.1 24.7 19.9 17.1 14.3 15.0 16.4 15.9
65–69 29.2 21.8 25.3 24.9 25.6 26.5 22.0 18.3 16.2 15.8 15.6 14.8
70–74 25.2 24.4 28.0 24.6 20.8 24.6 22.0 18.0 13.7 18.4 13.8 17.1
75–79 23.7 23.1 21.3 23.1 20.0 28.5 21.4 20.9 17.5 16.4 15.0 17.4
80–84 20.9 20.8 24.1 22.5 23.4 23.9 17.4 23.2 17.8 21.4 18.0 19.5
85+ 17.4 21.8 30.0 19.0 17.2 17.3 24.6 17.7 18.7 18.5 12.6 12.0
All ages 0–85+ years                  
Crude rate 12.7 12.5 12.6 11.7 11.4 12.6 10.5 10.1 8.6 9.1 8.3 7.7
AS rate (A) 13.5 13.3 13.3 12.2 11.9 12.9 10.7 10.3 8.6 9.0 8.2 7.6
AS rate (W) 11.5 11.3 11.2 10.3 10.0 10.9 9.0 8.7 7.3 7.7 7.0 6.4
Target age 20–69 years            
Crude rate 17.4 17.0 16.6 15.4 15.2 16.4 13.5 13.1 11.0 11.5 10.8 9.5
AS rate (A) 18.0 17.7 17.2 16.0 15.8 16.9 13.8 13.4 11.2 11.6 10.9 9.5
AS rate (W) 17.2 16.8 16.3 15.1 14.9 16.0 13.1 12.7 10.6 11.1 10.4 9.1
Notes 
1. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
2. In 2001 the Australian Bureau of Statistics (ABS) carried out a full population census and a national health survey. These led to the revision of 
the ABS estimated resident population (ERP) data, the introduction of a new Australian standard population for use in age standardisation 
and the production of new estimates of hysterectomy status among Australian women. The denominators for participation rates presented in 
this report have been calculated using the 2001 ABS National Health Survey hysterectomy fractions and the revised ERP values and age-
adjusted using the 2001 Australian standard population. The denominators for the equivalent rates in previous reports were calculated using 
the 1995 ABS National Health Survey hysterectomy fractions and unrevised ERP values and age-adjusted using the 1991 Australian standard 
population. The combined effect of these changes is that participation rates presented in this report are on average between 1 and 2 
percentage points lower than equivalent rates in previous reports. 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 14a: New cases of cervical cancer by age, states and territories, 1996–1999 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 2 1 1 0 0 0 0 0 4
20–24 11 8 16 3 0 5 0 0 43
25–29 61 37 48 13 16 7 5 3 190
30–34 105 57 72 30 26 12 0 2 304
35–39 147 94 103 33 24 24 9 10 444
40–44 130 108 91 52 24 8 5 6 424
45–49 134 91 65 34 25 6 5 7 367
50–54 122 60 54 21 14 5 3 6 285
55–59 65 62 41 19 16 5 4 4 216
60–64 80 60 47 17 18 7 1 2 232
65–69 89 49 51 22 12 4 4 0 231
70–74 83 57 28 22 12 4 3 2 211
75–79 65 45 37 14 14 5 1 1 182
80–84 53 46 19 15 8 2 2 0 145
85+ 35 29 20 13 5 0 1 0 103
All ages  
0–85+ years 1,182
 
804 693 308 214 94
 
43 
 
43 3,381
Target age 
20–69 years 944
 
626 588 244 175 83
 
36 
 
40 2,736
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 14b: Age-specific and age-standardised incidence rates of cervical cancer, states and 
territories, 1996–1999 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.2 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.2
20–24 1.2 1.2 3.1 1.1 0.0 8.1 0.0 0.0 1.6
25–29 6.3 5.0 9.0 4.6 7.5 10.7 9.5 8.0 6.6
30–34 10.9 7.9 14.0 10.8 11.9 17.7 0.0 5.9 10.6
35–39 14.6 12.7 19.0 11.3 10.2 31.7 17.5 31.9 14.9
40–44 13.9 15.6 18.0 18.5 10.8 11.2 10.0 21.9 15.2
45–49 15.5 14.1 13.7 13.3 11.8 9.1 10.2 30.4 14.1
50–54 16.4 10.9 13.3 10.2 7.7 8.9 7.8 35.2 12.9
55–59 11.1 14.4 13.3 12.0 11.2 11.0 15.7 38.6 12.6
60–64 15.6 15.8 18.6 12.9 14.2 17.7 5.3 29.9 15.7
65–69 17.9 13.5 21.4 18.2 9.6 10.5 25.3 0.0 16.5
70–74 17.7 16.6 12.8 20.6 9.7 11.3 20.8 63.3 16.0
75–79 17.3 16.6 21.0 16.7 13.9 17.1 9.1 49.3 17.3
80–84 20.8 24.9 15.9 25.6 11.7 9.8 29.2 0.0 20.1
85+ 16.3 17.8 20.0 24.9 8.4 0.0 19.5 0.0 16.8
All ages 0–85+ years             
Crude rate 9.3 8.6 10.1 8.6 7.1 9.8 6.9 12.1 9.0
AS rate (A) 9.2 8.5 10.4 8.8 6.9 9.9 7.7 16.3 9.0
95% CI 8.7–9.8 7.9–9.1 9.6–11.2 7.9–9.9 6.0–7.9 8.0–12.1 5.5–10.4 11.0–23.0 8.7–9.3
AS rate (W) 7.8 7.1 8.9 7.3 6.0 9.0 6.3 13.5 7.6
95% CI 7.3–8.3 6.6–7.6 8.3–9.6 6.5–8.2 5.2–6.9 7.2–11.0 4.6–8.6 9.4–18.7 7.4–7.9
Target age 20–69 years            
Crude rate 11.8 10.5 13.7 10.7 9.3 14.1 8.9 17.9 11.6
AS rate (A) 12.0 10.7 13.9 10.9 9.3 14.0 9.4 20.3 11.7
95% CI 11.2–12.8 9.9–11.6 12.8–15.1 9.6–12.4 8.0–10.8 11.1–17.3 6.5–13.1 14.2–28.1 11.3–12.2
AS rate (W) 11.4 10.2 13.4 10.3 9.0 13.9 8.9 19.0 11.2
95% CI 10.6–12.1 9.4–11.0 12.3–14.5 9.1–11.7 7.7–10.4 11.0–17.2 6.2–12.4 13.3–26.1 10.8–11.6
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 15a: Number of new cases of cervical cancer by age, states and territories, 1997–2000 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 3 1 1 0 0 0 0 0 5
20–24 12 5 12 2 0 4 0 0 35
25–29 63 32 46 13 16 9 6 2 187
30–34 118 55 76 28 28 10 2 2 319
35–39 122 69 91 31 22 20 8 8 371
40–44 123 95 85 44 21 8 5 5 386
45–49 119 85 56 39 24 5 5 4 337
50–54 113 54 46 20 18 6 2 4 263
55–59 73 56 40 15 14 5 3 3 209
60–64 78 58 54 16 21 4 1 2 234
65–69 86 47 44 19 12 6 3 0 217
70–74 78 55 34 21 14 3 3 1 209
75–79 64 45 32 14 17 4 2 3 181
80–84 51 40 19 18 10 1 2 0 141
85+ 35 25 20 11 6 1 1 0 99
All ages  
0–85+ years 1,138
 
722 656 291 223 86
 
43 
 
34 3,193
Target age 
20–69 years 907
 
556 550 227 176 77
 
35 
 
30 2,558
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 15b: Age-specific and age-standardised incidence rates of cervical cancer, states and 
territories, 1997–2000 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.4 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.2
20–24 1.4 0.8 2.4 0.8 0.0 6.7 0.0 0.0 1.3
25–29 6.4 4.3 8.5 4.6 7.6 13.9 11.3 5.3 6.4
30–34 12.3 7.6 14.7 10.0 13.0 15.1 4.0 5.8 11.2
35–39 12.0 9.3 16.5 10.5 9.4 26.7 15.6 25.0 12.3
40–44 12.9 13.5 16.4 15.4 9.3 11.1 10.0 17.8 13.6
45–49 13.6 13.0 11.6 14.9 11.2 7.5 10.2 16.7 12.8
50–54 14.5 9.3 10.7 9.1 9.4 10.1 4.9 21.8 11.3
55–59 12.0 12.6 12.3 9.1 9.5 10.7 11.1 26.5 11.7
60–64 14.9 15.0 20.5 11.7 16.2 9.9 5.1 28.4 15.4
65–69 17.5 13.1 18.5 15.7 9.8 15.9 18.7 0.0 15.6
70–74 16.6 16.0 15.3 19.3 11.4 8.5 20.5 30.7 15.8
75–79 16.4 15.9 17.5 15.9 16.2 13.3 16.9 142.5 16.5
80–84 19.6 21.4 15.5 30.4 14.4 4.8 27.8 0.0 19.2
85+ 15.5 14.6 18.9 19.9 9.5 5.8 17.9 0.0 15.3
All ages 0–85+ years             
Crude rate 8.9 7.6 9.4 8.0 7.4 9.0 6.9 9.4 8.4
AS rate (A) 8.7 7.5 9.6 8.1 7.1 9.0 7.4 14.1 8.4
95% CI 8.2–9.3 6.9–8.1 8.9–10.4 7.2–9.1 6.2–8.1 7.2–11.2 5.3–10.1 8.7–21.1 8.1–8.6
AS rate (W) 7.4 6.2 8.3 6.7 6.1 8.2 6.2 11.1 7.1
95% CI 7.0–7.9 5.8–6.7 7.6–8.9 6.0–7.6 5.3–7.0 6.6–10.2 4.5–8.3 7.3–16.0 6.8–7.3
Target age 20–69 years                 
Crude rate 11.3 9.3 12.6 9.8 9.3 13.1 8.6 13.1 10.7
AS rate (A) 11.3 9.4 12.7 9.9 9.3 13.0 8.8 14.7 10.8
95% CI 10.6–12.1 8.6–10.2 11.7–13.9 8.7–11.3 8.0–10.8 10.2–16.2 6.1–12.3 9.6–21.3 10.4–11.2
AS rate (W) 10.8 8.9 12.3 9.4 9.0 12.9 8.5 13.7 10.3
95% CI 10.1–11.5 8.1–9.6 11.3–13.4 8.2–10.7 7.7–10.4 10.2–16.2 5.9–11.8 9.1–19.9 9.9–10.7
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 16a: New cases of cervical cancer by histological type for women aged 20–69 years, Australia, 
1989–2000 
Histological type 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Squamous 687 641 650 612 597 630 545 529 449 484 466 398
Adenocarcinoma 116 148 144 141 142 192 147 148 129 140 127 117
Adeno-squamous 48 50 43 51 47 40 34 40 32 30 23 30
Other 56 64 61 43 59 62 45 39 36 29 35 30
Total 907 903 898 847 845 924 771 756 646 683 651 575
Micro-invasive 93 147 156 153 139 170 180 145 116 124 92 86
Source: National Cancer Statistics Clearing House (AIHW). 
 
 
 
Table 16b: Age-standardised incidence rates for cervical cancer by histological type for women 
aged 20–69 years, Australia, 1989–2000 
Histological type 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Squamous 13.7 12.6 12.5 11.5 11.2 11.5 9.8 9.4 7.8 8.2 7.8 6.6
Adenocarcinoma 2.3 2.9 2.8 2.7 2.6 3.5 2.6 2.6 2.2 2.4 2.1 1.9
Adeno-squamous 0.9 1.0 0.8 1.0 0.9 0.7 0.6 0.7 0.6 0.5 0.4 0.5
Other 1.1 1.3 1.1 0.8 1.1 1.1 0.8 0.7 0.6 0.5 0.6 0.5
Micro-invasive 1.8 2.8 2.9 2.8 2.6 3.0 3.2 2.5 2.0 2.1 1.5 1.4
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
Source: National Cancer Statistics Clearing House (AIHW). 
 58 
 
Table 17a: New cases of cervical cancer by histological type for women, all ages, Australia,  
1989–2000 
Histological type 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Squamous 808 769 792 753 706 780 675 667 546 609 574 520
Adenocarcinoma 136 171 172 157 164 222 173 168 159 166 147 137
Adeno-squamous 53 56 50 56 56 50 39 47 38 35 25 31
Other 75 77 80 62 87 78 70 51 54 48 47 54
Total 1,072 1,073 1,094 1,028 1,013 1,130 957 933 797 858 793 742
Micro-invasive 95 152 166 157 144 181 192 153 122 131 95 89
Source: National Cancer Statistics Clearing House (AIHW). 
 
 
 
Table 17b: Age-standardised incidence rates for cervical cancer by histological type for women, all 
ages, Australia, 1989–2000 
Histological type 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Squamous 10.2 9.5 9.6 8.9 8.3 8.9 7.6 7.3 5.9 6.4 6.0 5.3
Adenocarcinoma 1.7 2.1 2.1 1.9 1.9 2.5 1.9 1.8 1.7 1.8 1.5 1.4
Adeno-squamous 0.7 0.7 0.6 0.7 0.6 0.6 0.4 0.5 0.4 0.4 0.3 0.3
Other 0.9 1.0 0.9 0.7 1.0 0.9 0.8 0.6 0.6 0.5 0.5 0.5
Micro-invasive 1.2 1.8 2.0 1.8 1.7 2.0 2.1 1.7 1.3 1.4 1.0 0.9
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population. 
Source: National Cancer Statistics Clearing House (AIHW). 
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Indicator 5.3: Incidence by location 
Table 18: New cases of cervical cancer by age and location, 1993–1996 and 1997–2000 
 Major cities  Regional  Remote 
Age group 1993–1996 1997–2000 1993–1996 1997–2000 1993–1996 1997–2000 
0–4 0 0 0 0 0 0 
5–9 1 0 0 0 0 0 
10–14 0 0 0 0 0 0 
15–19 3 3 2 2 0 0 
20–24 31 23 11 11 1 1 
25–29 115 127 52 52 8 5 
30–34 248 208 140 98 13 8 
35–39 336 225 153 126 16 16 
40–44 321 250 151 112 15 16 
45–49 298 230 107 93 19 9 
50–54 202 180 99 73 10 6 
55–59 183 138 83 61 15 5 
60–64 200 148 86 74 6 8 
65–69 211 153 103 59 13 2 
70–74 176 151 81 52 10 2 
75–79 135 122 73 53 3 4 
80–84 97 97 44 42 4 1 
85+ 72 71 27 27 2 1 
All ages  
0–85+ years 2,628 2,127 1,211 933 135 83 
Target age 
20–69 years 2,144 1,683 985 758 116 75 
Note: The numbers are presented as 4-year rolling blocks of data. 
Source: National Cancer Statistics Clearing House (AIHW). 
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Table 19: Age-specific and age-standardised incidence rates for cervical cancer by age and  
location, 1993–1996 and 1997–2000 
 Major cities  Regional  Remote 
Age group 1993–1996 1997–2000 1993–1996 1997–2000 1993–1996 1997–2000 
0–4 0.0 0.0 0.0 0.0 0.0 0.0 
5–9 0.1 0.0 0.0 0.0 0.0 0.0 
10–14 0.0 0.0 0.0 0.0 0.0 0.0 
15–19 0.2 0.2 0.3 0.3 0.0 0.0 
20–24 1.5 1.2 1.6 1.7 1.3 1.5 
25–29 6.0 6.1 6.9 6.8 9.6 5.6 
30–34 12.6 10.6 16.1 12.0 14.7 10.1 
35–39 18.0 11.2 17.3 13.5 21.1 19.6 
40–44 18.1 13.3 18.6 12.6 22.8 23.2 
45–49 18.1 13.0 14.7 11.4 33.8 15.9 
50–54 16.2 11.6 17.2 10.1 24.6 12.1 
55–59 17.9 11.9 16.3 10.5 45.5 12.8 
60–64 21.5 15.1 18.3 14.4 24.0 27.0 
65–69 22.5 17.0 22.2 12.7 57.2 6.9 
70–74 20.7 17.2 20.3 12.0 60.6 12.8 
75–79 21.4 16.6 24.8 15.3 21.3 30.7 
80–84 21.2 19.7 21.0 17.9 50.6 11.7 
85+ 20.1 16.2 17.1 13.4 24.8 13.0 
All ages 0–85+ years      
AS rate (A) 11.1 8.3 11.1 7.9 18.4 10.1 
95% CI 10.7–11.6 8.0–8.7 10.5–11.7 7.4–8.4 15.3–21.9 8.0–12.6 
AS rate (W) 9.4 7.0 9.4 6.8 15.3 8.6 
95% CI 9.0–9.8 6.7–7.3 8.9–10.0 6.3–7.2 12.8–18.1 6.8–10.6 
Target age 20–69 years      
AS rate (A) 14.6 10.6 14.4 10.4 23.1 13.4 
95% CI 13.9–15.2 10.1–11.1 13.5–15.4 9.7–11.2 18.9–27.7 10.5–16.9 
AS rate (W) 13.8 10.1 13.7 10.0 21.7 12.7 
95% CI 13.2–14.4 9.6–10.6 12.9–14.6 9.3–10.8 17.8–25.9 10.0–16.0 
Notes 
1. The numbers are presented as 4-year rolling blocks of data. 
2. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
Source: National Cancer Statistics Clearing House (AIHW). 
 61 
 
Indicator 6.1: Mortality 
Table 20: Deaths from cervical cancer by age, Australia, 1982–2002 
Age group ’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01 ’02
0–4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0 0
20–24 1 1 0 0 2 2 0 1 1 3 0 0 0 0 1 0 3 1 1 0 2
25–29 7 8 10 6 6 5 3 3 10 5 5 2 6 3 1 2 6 2 4 1 2
30–34 13 12 13 20 12 15 12 21 14 13 15 11 11 7 13 8 5 6 10 11 6
35–39 12 18 19 17 16 20 15 18 30 25 19 25 11 16 23 18 19 7 12 12 9
40–44 22 20 20 18 26 20 24 24 36 19 27 32 28 21 20 16 19 18 14 19 13
45–49 24 28 26 21 24 19 27 31 36 29 26 23 35 32 30 28 16 25 27 23 15
50–54 29 26 25 25 25 24 19 27 17 21 13 29 37 26 13 21 24 15 19 21 32
55–59 41 40 21 31 41 32 41 20 25 25 23 20 26 34 22 24 15 14 19 20 15
60–64 47 36 41 41 41 28 41 33 34 33 31 25 24 30 21 22 28 15 24 25 19
65–69 39 49 43 52 50 46 41 54 43 35 25 30 37 37 29 30 19 21 26 20 18
70–74 35 30 33 43 32 55 34 48 25 37 45 38 33 43 41 36 28 30 37 28 18
75–79 34 20 29 29 23 29 35 29 32 30 32 28 30 30 38 32 26 26 25 30 26
80–84 21 22 26 26 23 20 34 24 8 22 35 24 26 27 22 27 26 19 23 28 26
85+ 18 21 21 29 24 16 17 22 25 32 23 24 24 20 24 30 31 21 26 24 26
All ages 
0–85+ years 342 330 327 359 343 329 343 355 337 329 319 311 329 328 296 294 265 220 267 262 227
Target age 
20–69 years 234 238 218 230 242 210 222 231 246 208 184 197 216 207 172 169 154 124 156 152 131
Note: Deaths were derived by year of registration. 
Source: AIHW Mortality Database. 
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Table 21: Age-specific and age-standardised death rates for cervical cancer by age, Australia,  
1982–2002 
Age group ’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01 ’02
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.1 0.1 0.0 0.0 0.3 0.3 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.2 0.2 0.0 0.3
25–29 1.1 1.2 1.5 0.9 0.9 0.7 0.4 0.4 1.4 0.7 0.7 0.3 0.9 0.4 0.1 0.3 0.8 0.3 0.6 0.1 0.3
30–34 2.1 1.9 2.1 3.1 1.9 2.3 1.8 3.0 2.0 1.8 2.0 1.5 1.5 0.9 1.8 1.1 0.7 0.8 1.4 1.5 0.8
35–39 2.2 3.2 3.2 2.8 2.5 3.1 2.3 2.7 4.6 3.7 2.7 3.6 1.5 2.2 3.1 2.4 2.5 0.9 1.6 1.6 1.2
40–44 5.1 4.5 4.3 3.7 5.4 3.7 4.1 3.9 5.9 2.9 4.3 5.0 4.3 3.1 2.9 2.3 2.7 2.5 1.9 2.6 1.7
45–49 6.4 7.6 6.9 5.2 5.7 4.4 6.3 6.9 7.6 5.8 4.9 3.9 5.9 5.2 4.7 4.4 2.4 3.8 4.0 3.4 2.2
50–54 7.9 7.2 7.0 7.1 6.8 6.4 4.9 7.1 4.2 5.0 3.0 6.8 8.2 5.6 2.6 3.9 4.2 2.5 3.0 3.2 4.9
55–59 11.1 10.7 5.5 8.4 11.1 8.8 11.3 5.4 6.8 7.1 6.2 5.2 6.9 8.7 5.3 5.7 3.5 3.1 4.0 4.0 2.8
60–64 14.2 10.6 11.5 11.3 11.2 7.7 11.1 9.0 9.3 9.0 8.6 7.1 6.6 8.5 5.8 6.0 7.5 3.9 6.0 6.1 4.5
65–69 13.5 16.8 14.9 17.8 16.4 14.6 12.5 15.7 12.4 10.0 7.2 8.5 10.5 10.5 8.3 8.5 5.4 6.1 7.5 5.8 5.1
70–74 15.0 12.5 13.2 16.6 12.3 20.5 12.8 18.1 9.4 13.2 15.4 12.6 10.5 13.4 12.6 11.0 8.5 9.0 11.1 8.4 5.4
75–79 21.3 11.6 16.7 16.0 11.8 14.8 17.1 13.7 14.7 13.5 14.1 12.4 13.3 13.0 15.7 12.5 9.7 9.3 8.7 10.3 8.8
80–84 19.6 19.9 23.4 22.9 19.0 15.8 26.6 17.6 5.6 14.8 23.3 14.9 15.8 15.9 12.2 15.0 14.3 10.4 12.1 13.9 12.3
85+ 22.7 25.6 24.7 33.1 24.9 16.1 16.7 20.9 23.2 29.4 19.5 19.3 18.4 14.6 16.6 20.1 19.8 12.6 14.8 13.1 13.6
All ages 0–85+ years                   
AS rate (A) 5.1 4.9 4.7 5.0 4.7 4.4 4.5 4.5 4.2 4.0 3.8 3.6 3.8 3.7 3.2 3.1 2.7 2.2 2.6 2.5 2.1
AS rate (W) 4.0 3.8 3.6 3.8 3.7 3.4 3.4 3.5 3.3 3.1 2.8 2.8 2.9 2.8 2.4 2.3 2.1 1.7 2.0 1.9 1.6
Target age 20–69 years                    
AS rate (A) 5.4 5.4 4.9 5.0 5.2 4.4 4.6 4.6 4.8 4.0 3.5 3.8 4.1 3.8 3.0 3.0 2.7 2.1 2.6 2.5 2.1
AS rate (W) 5.0 5.0 4.5 4.6 4.8 4.1 4.2 4.3 4.5 3.8 3.3 3.4 3.7 3.5 2.8 2.7 2.5 1.9 2.4 2.3 1.9
Notes  
1. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W).  
2. In 2001 the Australian Bureau of Statistics (ABS) carried out a full population census and a national health survey. These led to the revision of 
the ABS estimated resident population (ERP) data, the introduction of a new Australian standard population for use in age standardisation 
and the production of new estimates of hysterectomy status among Australian women. The denominators for participation rates presented in 
this report have been calculated using the 2001 ABS National Health Survey hysterectomy fractions and the revised ERP values and age-
adjusted using the 2001 Australian standard population. The denominators for the equivalent rates in previous reports were calculated using 
the 1995 ABS National Health Survey hysterectomy fractions and unrevised ERP values and age-adjusted using the 1991 Australian standard 
population. The combined effect of these changes is that participation rates presented in this report are on average between 1 and 2 
percentage points lower than equivalent rates in previous reports. 
Source: AIHW Mortality Database. 
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Table 22: Deaths from cervical cancer by age, states and territories, 1995–1998 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 1 0 0 0 0 0 0 0 1
20–24 0 2 2 0 0 0 0 0 4
25–29 0 3 5 2 1 0 1 0 12
30–34 8 8 7 7 2 1 0 0 33
35–39 28 15 13 11 5 3 0 1 75
40–44 35 14 12 6 3 2 3 1 75
45–49 42 22 14 11 5 4 4 5 107
50–54 36 18 16 8 2 2 3 0 84
55–59 33 14 20 12 8 6 2 1 95
60–64 35 22 20 6 7 9 1 2 101
65–69 43 33 17 12 5 3 2 2 116
70–74 56 38 26 8 12 6 2 1 148
75–75 46 28 31 5 10 6 1 1 127
80–84 33 31 14 9 14 1 1 0 102
85+ 38 24 12 16 10 3 2 0 104
All ages 
0–85+ years 431 269 207 112 83 46 22 14 1,183
Target age 
20–69 years 258 149 125 74 38 30 16 12 701
Notes 
1. Numbers were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.  
2. Deaths were derived by year and state of registration. 
Source: AIHW Mortality Database. 
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Table 23: Age-specific and age-standardised death rates for cervical cancer by age, states and 
territories, 1995–1998 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.0 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.1
25–29 0.0 0.4 0.9 0.7 0.5 0.0 1.9 0.0 0.4
30–34 0.8 1.1 1.3 2.5 0.9 1.4 0.0 0.0 1.1
35–39 2.8 2.0 2.4 3.8 2.1 3.9 0.0 3.2 2.6
40–44 3.8 2.0 2.4 2.2 1.3 2.8 5.9 3.7 2.7
45–49 5.0 3.4 3.0 4.3 2.4 6.0 8.2 21.9 4.2
50–54 5.0 3.4 4.2 4.1 1.2 3.7 8.2 0.0 4.0
55–59 5.7 3.3 6.7 7.7 5.6 13.3 8.1 10.0 5.7
60–64 6.8 5.8 8.0 4.6 5.5 22.8 5.4 31.2 7.0
65–69 8.5 8.9 7.1 9.9 3.9 7.8 12.7 44.5 8.2
70–74 12.0 11.0 11.8 7.5 9.6 16.6 13.8 33.1 11.3
75–75 12.7 10.7 18.2 6.2 10.3 21.1 9.6 50.7 12.6
80–84 12.9 16.6 11.8 15.2 20.2 4.8 14.8 0.0 14.3
85+ 18.4 15.3 12.6 32.1 17.4 19.1 41.5 0.0 17.9
All ages 0–85+ years    
AS rate (A) 3.3 2.8 3.2 3.3 2.4 4.7 4.3 7.9 3.2
95% CI 3.0–3.7 2.5–3.1 2.8–3.7 2.7–4.0 1.9–3.0 3.4–6.2 2.6–6.6 3.6–13.9 3.0–3.4
AS rate (W) 2.5 2.1 2.5 2.6 1.8 3.7 3.3 6.2 2.4
95% CI 2.3–2.8 1.8–2.4 2.1–2.9 2.1–3.1 1.4–2.2 2.6–4.9 2.0–4.9 3.0–10.7 2.3–2.6
Target age 20–69 years    
AS rate (A) 3.4 2.6 3.1 3.5 2.0 5.1 4.4 8.6 3.1
95% CI 3.0–3.8 2.2–3.0 2.6–3.7 2.7–4.4 1.4–2.8 3.4–7.2 2.4–7.1 3.8–15.4 2.9–3.4
AS rate (W) 3.1 2.4 2.9 3.2 1.9 4.7 4.0 7.9 2.9
95% CI 2.7–3.5 2.0–2.8 2.4–3.5 2.5–4.1 1.3–2.6 3.1–6.7 2.2–6.5 3.5–14.0 2.7–3.1
Notes  
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.  
2. Deaths were derived by year and state of registration. 
3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W).  
Source: AIHW Mortality Database. 
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Table 24: Deaths from cervical cancer by age, states and territories, 1999–2002 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0 
5–9 0 0 0 0 0 0 0 0 0 
10–14 0 0 0 0 0 0 0 0 0 
15–19 0 0 0 0 0 0 0 0 0 
20–24 4 0 0 0 0 0 0 0 4 
25–29 1 3 2 1 0 0 1 1 9 
30–34 5 4 11 9 2 1 1 0 33 
35–39 14 9 8 2 2 2 1 2 40 
40–44 18 12 20 5 4 1 2 2 64 
45–49 29 16 19 11 13 1 0 1 90 
50–54 33 16 13 7 8 6 1 3 87 
55–59 25 13 14 7 5 2 1 1 68 
60–64 31 15 20 9 6 2 0 0 83 
65–69 28 12 16 14 7 4 3 1 85 
70–74 36 29 23 17 4 3 0 1 113 
75–79 31 30 16 13 10 3 3 1 107 
80–84 30 27 16 14 5 3 0 1 96 
85+ 35 22 16 12 7 5 0 0 97 
All ages 
0–85+ years 320 208 194 121 73 33 13 14 976 
Target age 
20–69 years 188 100 123 65 47 19 10 11 563 
Notes 
1. Numbers were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.  
2. Deaths were derived by year and state of registration. 
Source: AIHW Mortality Database. 
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Table 25: Age-specific and age-standardised death rates for cervical cancer by age, states and 
territories, 1999–2002 
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2
25–29 0.1 0.4 0.4 0.4 0.0 0.0 1.9 2.7 0.3
30–34 0.5 0.5 2.0 3.2 0.9 1.5 2.0 0.0 1.1
35–39 1.4 1.2 1.4 0.7 0.9 2.8 2.0 6.1 1.3
40–44 1.8 1.6 3.6 1.7 1.7 1.4 3.9 6.8 2.2
45–49 3.2 2.4 3.8 4.0 6.0 1.5 0.0 3.9 3.3
50–54 3.9 2.6 2.8 2.9 3.9 9.4 2.2 14.3 3.5
55–59 3.8 2.7 3.8 3.8 3.1 3.9 3.2 7.5 3.5
60–64 5.6 3.7 6.9 6.0 4.4 4.6 0.0 0.0 5.2
65–69 5.7 3.3 6.6 11.2 5.8 10.7 17.9 19.7 6.1
70–74 7.6 8.4 10.1 15.1 3.3 8.5 0.0 28.0 8.5
75–75 7.5 10.0 8.3 13.8 9.1 9.7 23.0 42.7 9.3
80–84 10.7 13.4 12.0 22.0 6.7 13.7 0.0 65.2 12.2
85+ 13.9 11.7 13.6 19.5 10.1 26.2 0.0 0.0 13.6
All ages 0–85+ years    
AS rate (A) 2.3 2.0 2.7 3.3 2.1 3.1 2.3 6.7 2.4
95% CI 2.0–2.5 1.7–2.3 2.3–3.1 2.7–3.9 1.6–2.7 2.1–4.3 1.2–3.9 3.0–12.2 2.2–2.5
AS rate (W) 1.7 1.4 2.1 2.4 1.6 2.3 1.8 4.9 1.8
95% CI 1.5–1.9 1.2–1.7 1.8–2.4 2.0–2.9 1.3–2.1 1.5–3.3 1.0–3.2 2.4–8.6 1.7–1.9
Target age 20–69 years    
AS rate (A) 2.3 1.6 2.7 2.8 2.4 3.1 2.6 5.5 2.3
95% CI 2.0–2.6 1.3–2.0 2.3–3.3 2.1–3.5 1.7–3.1 1.8–4.8 1.2–4.9 2.5–10.2 2.1–2.5
AS rate (W) 2.1 1.5 2.5 2.6 2.2 2.8 2.5 5.0 2.1
95% CI 1.8–2.4 1.2–1.8 2.1–3.0 2.0–3.3 1.6–2.9 1.7–4.3 1.2–4.6 2.3–9.3 2.0–2.3
Notes 
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.  
2. Deaths were derived by year and state of registration. 
3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W).  
Source: AIHW Mortality Database. 
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Indicator 6.2: Mortality by location 
Table 26: Deaths from cervical cancer by age and location, 1995–1998 and 1999–2002 
 Major cities  Regional  Remote 
Age group 1995–1998 1999–2002 1995–1998 1999–2002 1995–1998 1999–2002
0–4 0 0 0 0 0 0
5–9 0 0 0 0 0 0
10–14 0 0 0 0 0 0
15–19 1 0 0 0 0 0
20–24 3 1 1 3 0 0
25–29 6 4 5 5 0 0
30–34 20 21 12 8 1 4
35–39 46 23 25 17 2 0
40–44 45 35 28 24 2 5
45–49 63 66 34 22 7 0
50–54 57 55 25 30 2 1
55–59 61 41 32 24 1 3
60–64 56 52 39 29 5 0
65–69 73 53 36 30 7 2
70–74 91 73 52 36 5 3
75–75 82 70 43 35 2 1
80–84 72 64 26 28 3 2
85+ 76 64 28 30 0 3
All ages  
0–85+ years 751 621 387 321 38 26
Target age 
20–69 years 430 350 238 192 28 17
Notes 
1. Deaths were derived from place of usual residence and by year of registration. 
2. The number of deaths is presented as 4-year rolling blocks of data. 
Source: AIHW Mortality Database. 
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Table 27: Age-specific and age-standardised death rates for cervical cancer by age and location, 
1995–1998 and 1999–2002 
 Major cities  Regional  Remote 
Age group 1995–1998 1999–2002 1995–1998 1999–2002 1995–1998 1999–2002
0–4 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.1 0.0 0.0 0.0 0.0 0.0
20–24 0.2 0.0 0.1 0.5 0.0 0.0
25–29 0.3 0.2 0.7 0.6 0.0 0.5
30–34 1.0 1.0 1.4 1.0 1.2 5.0
35–39 2.4 1.1 2.7 1.9 2.5 0.2
40–44 2.5 1.8 3.3 2.6 3.5 6.5
45–49 3.7 3.6 4.5 2.6 12.5 0.4
50–54 4.1 3.2 3.9 3.9 4.5 2.4
55–59 5.7 3.2 6.0 3.7 3.4 8.3
60–64 6.0 5.1 8.1 5.3 18.8 1.3
65–69 7.9 5.9 7.7 6.4 31.8 8.6
70–74 10.4 8.3 12.5 8.1 29.6 15.2
75–75 12.1 9.0 13.6 9.5 16.5 9.1
80–84 14.9 12.2 11.9 11.3 34.9 26.4
85+ 19.2 13.2 15.6 13.4 5.9 35.8
All ages 0–85+ years  
AS rate (A) 3.0 2.3 3.3 2.5 5.9 3.6
95% CI 2.8–3.2 2.1–2.5 3.0–3.7 2.2–2.8 4.1–8.1 2.3–5.3
AS rate (W) 2.3 1.7 2.6 1.9 4.6 2.6
95% CI 2.1–2.4 1.6–1.9 2.3–2.8 1.7–2.1 3.2–6.2 1.7–3.9
Target age 20–69 years  
AS rate (A) 2.9 2.2 3.3 2.5 6.0 3.0
95% CI 2.6–3.2 2.0–2.4 2.9–3.8 2.1–2.9 3.9–8.7 1.7–4.9
AS rate (W) 2.7 2.0 3.1 2.3 5.5 2.8
95% CI 2.4–2.9 1.8–2.2 2.7–3.5 2.0–2.7 3.6–7.9 1.6–4.6
Notes 
1. The age-standardised rates are presented as 4-year rolling blocks of data.  
2. Deaths were derived from place of usual residence and by year of registration.  
3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
Source: AIHW Mortality Database. 
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Indicator 6.3: Mortality by Indigenous status 
Table 28: Number of deaths and age-specific and age-standardised death rates for cervical cancer by 
age and Indigenous status, Queensland, South Australia, Western Australia and Northern 
Territory, 1999–2002 
 Indigenous Non-Indigenous 
Age group Number Rate Number Rate
0–4 0 0.0 0 0.0
5–9 0 0.0 0 0.0
10–14 0 0.0 0 0.0
15–19 0 0.0 0 0.0
20–24 0 0.0 0 0.0
25–29 1 2.8 3 0.3
30–34 4 11.9 18 1.7
35–39 0 0.0 14 1.3
40–44 7 30.3 24 2.2
45–49 6 32.8 37 3.7
50–54 2 15.1 29 3.1
55–59 1 11.3 26 3.6
60–64 1 15.7 33 5.7
65–69 2 41.7 35 7.2
70–74 5 150.7 40 8.7
75+ 3 77.9 107 11.6
All ages 0–75+ years 32 366 
AS rate (A) 18.9  2.5
95% CI 11.7–28.1  2.3–2.8
AS rate (W) 14.0  1.9
95% CI 9.1–20.2  1.7–2.1
Target age 20–69 years 24 219 
AS rate (A) 14.9  2.5
95% CI 9.1–22.6  2.2–2.8
AS rate (W) 13.7  2.3
95% CI 8.5–20.8  2.0–2.6
Notes  
1. Deaths were derived by state and year of registration. 
2. The number of deaths and the age-standardised rates are presented as a 4-year rolling block of data. 
3. Rates are expressed per 100,000 women and age-standardised to the Australian 2001 population (A) and the WHO World Standard  
Population (W). 
4. Only Queensland, South Australia, Western Australia and the Northern Territory have Indigenous death registration data considered to be 
of a publishable standard. 
Source: AIHW Mortality Database. 
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Appendixes 
Appendix A: Cervical cancer—symptoms, detection 
and treatment 
Cervical cancer affects the cells of the cervix, which is the lower part of the womb or uterus 
as it joins the inner end of the vagina. Like other cancers, cervical cancer is a disease where 
normal cells change, begin to multiply out of control, and form a growth or tumour. The 
cancer may arise from the squamous cells at the transformation zone where the squamous 
cells on the outside of the cervix join the columnar cells in the lining of the cervical canal 
(squamous cell carcinoma) or from the cells in the cervical canal (adenocarcinoma). Over 
two-thirds of cervical cancers are squamous cell carcinomas, which are most easily detected 
on the Pap smear, and about 20% are adenocarcinomas. If not detected early, the tumour can 
invade local tissue and spread (metastasise) to other parts of the body. The main symptoms 
of cervical cancer are unusual bleeding from the vagina, and very rarely an unusual vaginal 
discharge. However, these symptoms are quite common and may not be due to cancer. 
A cervical cancer may take 10 or more years to develop, but before this the cells may show 
pre-cancerous changes. These early changes can be detected by a Pap smear (which is 
described in more detail below), and with early treatment of these abnormalities, cervical 
cancer can be prevented. The most recent classification of these pre-cancerous lesions has 
two levels of severity: low-grade epithelial abnormalities (LGEA) and high-grade epithelial 
abnormalities (HGEA). An earlier classification described various grades of cervical intra-
epithelial neoplasia (CIN). Low-grade abnormalities include minor changes in squamous 
cells and CIN 1, and high-grade abnormalities include CIN 2, CIN 3, squamous carcinoma-
in-situ, adenocarcinoma-in-situ and invasive carcinoma (squamous or adenocarcinoma).  
The Pap smear is the most common way to detect pre-cancerous changes, which rarely cause 
any symptoms. The test involves a doctor inserting a speculum into the vagina and gently 
scraping the surface of the cervix. This process collects cells that are transferred onto a slide 
or into a special liquid, which is then sent to a pathology laboratory for assessment. Pap 
smears are offered by general practitioners, gynaecologists, family planning clinics, women’s 
health centres, hospital outpatient clinics and, in some circumstances, specially trained 
nurses.  
If the Pap smear shows an abnormality, the woman may be advised to have a repeat smear if 
the abnormality is low-grade or she may be advised to have a colposcopy. With colposcopy, 
a doctor is able to look directly at the cervix under magnification using an instrument called 
a colposcope. Using a special stain the doctor can highlight any suspicious area, which may 
be pre-cancerous or cancerous. The doctor will then take a tissue sample (a biopsy) of the 
suspicious area for further examination by the pathologist. 
Pre-cancerous changes can be easily and effectively treated to prevent the progression to 
cervical cancer. The type of treatment depends on whether the change observed is low or 
high grade, the woman’s age and general health, whether she wants to have children, and 
her preferences.  
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There is a range of treatments for pre-cancerous changes, including laser treatment, loop 
excision (LLETZ), cryosurgery (cold coagulation), electrodiathermy, or cone biopsy (either by 
laser or by scalpel). In a small number of instances, a hysterectomy may be necessary. 
For invasive cancer, a cone biopsy or hysterectomy is generally performed. If the cancer cells 
are detected on the surface of the cervix only, it may be treated by a cone biopsy. If it has 
invaded deeper into the cervix, a hysterectomy is generally performed. In advanced cases, a 
radical hysterectomy is needed to remove the cervix and uterus along with a margin of tissue 
around the cervix and lymph nodes from the pelvis. Radiotherapy is sometimes used as well 
as surgery, and for more advanced cases it may be used on its own. 
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Appendix B: Data sources and limitations 
All data used in this report are based on calendar years. Data are derived from multiple 
sources and are summarised below. 
Table B1: Cervical cancer screening indicators data sources 
Indicator Description Data source 
1 Participation rate for cervical cancer screening National Cervical Screening Program 
2 Early re-screening National Cervical Screening Program 
3 Low-grade abnormality detection National Cervical Screening Program 
4 High-grade abnormality detection National Cervical Screening Program 
5.1 Incidence of micro-invasive cervical cancer  
National Cancer Statistics Clearing House (ICD-10 C53) 
National Cancer Statistics Clearing House 
5.2 Incidence of squamous, adenocarcinoma, adeno-
squamous and other cervical cancer (ICD-10 C53) 
National Cancer Statistics Clearing House 
5.3 Incidence by location (ICD-10 C53) National Cancer Statistics Clearing House 
6.1 Mortality from cervical cancer 
(ICD-9 180 for data up to and including 1996; ICD-10 
C53 for data from 1997 onwards) 
AIHW Mortality Database 
6.2 Mortality by location AIHW Mortality Database 
6.3 Mortality by Indigenous status AIHW Mortality Database 
Population data 
The Australian Bureau of Statistics estimated resident female population has been used to 
calculate incidence and mortality rates. Participation rates were calculated using the average 
of the 2001 and 2002 estimated resident female population (see Appendix D for tables). There 
may be some variation in published participation rates because national rates use estimated 
resident population data in the denominator whereas local data analysis may use census 
counts. The denominator population used to calculate cervical screening participation rates 
has been adjusted by the estimated proportion of women who have had a hysterectomy by 
age. These data were derived from the 2001 National Health Survey, and are tabled in 
Appendix D.  
The age-standardised rates in this publication are calculated using the total estimated 2001 
mid-year Australian resident population. Where appropriate, rates are also standardised to 
the WHO World Standard Population for international comparison. Both the Australian and 
the WHO World Standard Populations are in Appendix D. 
Indigenous mortality data 
Due to the difficulties of Indigenous identification, mortality data used in Indicator 10 are 
based on deaths in Queensland (for 1998, 1999, 2000, 20001 and 2002), Western Australia, 
South Australia and the Northern Territory only. 
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Other data limitations 
• Hysterectomy fractions are calculated using national data derived from the National 
Health Survey using aggregate data that do not necessarily reflect variation at the state or 
territory level. In this report, data from the 2001 National Health Survey have been used.  
• Participation rates will be underestimates to the extent that a small percentage of women 
choose to opt-off local registers and have been excluded from the statistics in this report. 
• The participation numbers for states and territories other than Western Australia and 
Australian Capital Territory, and the Australian totals, may be overestimated because of 
double counting of some women in registers. This may be the result of difficulty in 
identifying state or territory of residence for women in border areas and the inclusion in 
registers of women resident overseas. 
• Participation rates published by state and territory programs may differ from those in 
this publication because of variation in denominators used.  
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Appendix C: Methods 
This section describes the methods employed to calculate the estimates presented in the 
tables in the body of this publication.  
Crude rates 
A crude rate is defined as the number of events over a specified period of time (e.g. a year) 
divided by the total population. For example, a crude cancer incidence rate is similarly 
defined as the number of new cases of cancer in a specified period of time divided by the 
population at risk. Crude death rates and cancer incidence rates are expressed in this report 
as rates per 100,000 population. Crude participation rate is expressed as a percentage. 
Age-specific rates 
Age-specific rates are calculated by dividing the number of cases occurring in each specified 
age group by the corresponding population in the same age group expressed as a percentage 
or a rate per 1,000 or 100,000 population. This rate may be calculated for particular age and 
sex groupings, for example: 
 
                                      
years 5450 aged population female  2000
2000)(year  years 54–50 aged cases New  
−
=  100,000 ×  
 
           
 623,134
58 =  100,000×    
           100,000per  9.3 =  
Age-standardised rates (AS rate) 
Rates are adjusted for age to facilitate comparisons between populations that have different 
age structures, e.g. between youthful and ageing communities. There are two different 
methods commonly used to adjust for age. In this publication we use direct standardisation 
in which age-specific rates are multiplied against a constant population (the Australian 2001 
Population Standard unless otherwise specified). This effectively removes the influence of 
age structure on the summary rate that is described as the age-standardised rate. The method 
may be used for the calculation of participation, incidence and mortality rates. The method 
used for this calculation comprises three steps:  
Step 1: Calculate the age-specific rate (as shown above) for each age group. 
Step 2: Calculate the expected number of cases in each 5-year age group by multiplying the 
age-specific rates by the corresponding standard population and dividing by 100,000, giving 
the expected number of cases. 
Step 3: Sum the expected number of cases in each age group to give the age-standardised 
rate. Divide this sum by the total of the standard population and multiply by 100,000. 
Age-specific  
cervical cancer 
incidence rate in  
females aged 50–54 
in the year 2000 
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Confidence intervals 
Population numbers for incidence, mortality and screening have a natural level of variability 
for a single year above and below what might be expected in the mean over many years. The 
percentage variability is small for large population numbers but high for small numbers such 
as mortality in a young age group. One measure of the likely difference is the standard error, 
which indicates the extent to which a population number might have varied by chance in 
only one year of data. 
In the 95% confidence interval there are about 19 chances in 20 that the difference will be less 
than two standard errors. 
The 95% confidence intervals in this report were calculated using a method for obtaining 
approximate confidence intervals for a weighted sum of Poisson parameters developed by 
Dobson et al. (1991).  
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Appendix D: Population data 
Table D1: Australian Standard Population(a) and WHO World Standard Population(b) 
Age group World Standard Population (W) Australian 2001 Population Standard (A) 
0–4 8.86 1,282,357 
5–9 8.69 1,351,664 
10–14 8.60 1,353,177 
15–19 8.47 1,352,745 
20–24 8.22 1,302,412 
25–29 7.93 1,407,081 
30–34 7.61 1,466,615 
35–39 7.15 1,492,204 
40–44 6.59 1,479,257 
45–49 6.04 1,358,594 
50–54 5.37 1,300,777 
55–59 4.55 1,008,799 
60–64 3.72 822,024 
65–69 2.96 682,513 
70–74 2.21 638,380 
75–79 1.52 519,356 
80–84 0.91 330,050 
85+ 0.63 265,235 
Total 100.03 19,413,240 
Sources  
(a) ABS 2002. 
(b) Ahmad et al. 2002. 
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Table D2: Hysterectomy fractions for women aged 15–80+ years,  
Australia, 2001  
Age group % of women who have not had a hysterectomy 
18–19 100.0 
20–24 100.0 
25–29 100.0 
30–34 98.9 
35–39 95.6 
40–44 90.6 
45–49 82.5 
50–54 76.5 
55–59 66.2 
60–64 68.9 
65–69 66.8 
70–74 68.1 
75–79 67.9 
80+ 69.0 
Total  85.5 
Source: ABS 2001 National Health Survey. 
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Table D3: Estimated resident female populations, by age, states and territories, June 1999  
Age 
group NSW Vic Qld WA SA Tas ACT  NT  Australia 
0–4 212,896 150,627 118,871 62,017 46,320 15,570 10,429 8,483 625,323 
5–9 219,794 158,442 125,119 65,462 48,658 16,689 10,934 8,350 653,586 
10–14 215,692 156,263 122,701 67,214 49,281 17,108 11,032 7,512 646,949 
15–19 210,302 153,602 123,744 64,498 48,892 16,594 11,696 7,028 636,395 
20–24 212,148 160,173 122,506 63,953 47,281 14,433 12,859 7,749 641,165 
25–29 247,927 186,116 136,149 70,807 52,790 15,998 13,384 9,528 732,790 
30–34 238,251 182,559 129,445 69,843 53,571 16,243 12,485 8,590 711,121 
35–39 256,665 187,952 139,681 74,926 58,791 18,752 12,924 8,147 757,978 
40–44 240,204 176,816 131,091 72,122 56,405 17,996 12,556 7,107 714,395 
45–49 221,730 164,786 122,752 66,644 53,974 16,768 12,354 6,217 665,314 
50–54 200,666 148,449 111,303 56,992 49,678 15,179 10,806 4,770 597,901 
55–59 154,990 113,020 83,131 42,273 37,332 11,927 6,949 3,007 452,671 
60–64 133,768 98,142 67,264 35,212 32,754 10,225 5,079 1,780 384,242 
65–69 122,098 89,625 59,056 30,382 30,459 9,315 3,989 1,173 346,104 
70–74 118,688 86,729 55,999 27,589 30,979 8,800 3,718 821 333,331 
75–79 100,171 72,968 46,664 22,867 26,840 7,685 3,108 564 280,869 
80–84 65,814 46,704 30,935 14,744 17,445 5,217 1,872 330 183,067 
85+ 58,306 44,007 27,284 14,204 16,231 4,380 1,434 260 166,106 
Total 3,230,110 2,376,980 1,753,695 921,749 757,681 238,879 157,608 91,416 9,529,307 
Source: AIHW Population Database based on estimated resident population data compiled by ABS. 
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Table D4: Estimated resident female populations, states and territories, June 2000 
Age 
group NSW Vic Qld WA SA Tas ACT  NT  Australia 
0–4 212,248 150,048 119,160 61,978 45,470 15,236 10,327 8,521 623,100 
5–9 220,812 159,285 126,800 65,717 48,675 16,633 10,858 8,396 657,321 
10–14 217,827 157,685 124,667 67,662 49,127 16,792 11,001 7,584 652,475 
15–19 214,103 157,159 126,223 66,450 49,724 16,702 11,844 7,147 649,402 
20–24 211,077 158,650 121,765 63,301 46,456 14,071 12,778 7,714 635,881 
25–29 247,422 184,117 135,753 69,930 51,486 15,541 13,323 9,359 727,009 
30–34 240,000 185,289 131,615 70,453 53,291 16,169 12,582 8,816 718,323 
35–39 255,711 188,110 140,417 74,799 57,901 18,242 12,852 8,251 756,421 
40–44 244,599 180,407 134,766 73,321 57,577 18,175 12,722 7,226 728,900 
45–49 224,723 166,671 124,670 68,226 54,103 16,897 12,337 6,405 674,128 
50–54 207,920 154,790 116,441 60,200 51,550 15,772 11,315 5,088 623,134 
55–59 161,449 117,249 88,394 44,223 39,070 12,350 7,449 3,255 473,483 
60–64 137,200 100,964 70,601 36,564 33,626 10,633 5,336 1,900 396,853 
65–69 121,266 89,014 59,494 30,663 30,036 9,263 4,102 1,235 345,081 
70–74 118,405 86,798 56,363 28,027 30,669 8,777 3,742 853 333,643 
75–79 102,665 74,696 48,012 23,354 27,472 7,758 3,225 560 287,744 
80–84 68,156 48,613 32,106 15,366 18,064 5,345 1,975 369 190,000 
85+ 61,529 46,288 28,770 15,009 16,988 4,673 1,607 286 175,151 
Total 3,267,112 2,405,833 1,786,017 935,243 761,285 239,029 159,375 92,965 9,648,049 
Source: AIHW Population Database based on estimated resident population data compiled by ABS. 
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Table D5: Estimated resident female populations, states and territories, June 2001 
Age 
group NSW Vic Qld WA SA Tas ACT  NT  Australia 
0–4 213,086 150,321 120,456 61,905 44,962 15,150 10,272 8,594 624,858 
5–9 220,990 159,060 127,970 65,655 48,495 16,360 10,824 8,379 657,874 
10–14 220,821 159,577 127,233 68,044 48,716 16,771 11,073 7,723 660,094 
15–19 218,197 160,653 128,582 68,177 50,536 16,636 12,060 7,173 662,077 
20–24 212,719 160,769 123,091 63,913 46,344 13,999 13,122 7,616 641,636 
25–29 241,462 178,268 132,503 67,908 49,170 14,721 13,030 9,029 706,171 
30–34 248,361 191,148 136,310 72,069 53,575 16,257 12,838 9,047 739,696 
35–39 253,112 187,977 139,855 74,293 56,832 17,524 12,849 8,204 750,770 
40–44 250,299 184,241 138,896 74,398 58,196 18,437 12,815 7,428 744,821 
45–49 227,525 168,515 127,283 69,797 54,391 17,073 12,302 6,543 683,539 
50–54 215,107 160,647 121,798 63,711 53,246 16,338 11,817 5,513 648,237 
55–59 168,272 122,587 93,692 46,062 41,110 12,818 7,906 3,418 495,911 
60–64 140,535 102,654 74,133 37,870 34,124 10,988 5,594 2,111 408,042 
65–69 121,568 89,321 60,179 31,244 29,788 9,248 4,265 1,290 346,923 
70–74 118,705 86,795 57,118 28,484 30,325 8,740 3,731 918 334,826 
75–79 103,805 75,974 48,959 23,787 27,745 7,819 3,320 588 292,000 
80–84 72,230 51,628 34,293 16,288 19,239 5,547 2,159 412 201,800 
85+ 64,220 48,296 30,155 15,998 17,672 4,899 1,765 307 183,313 
Total  3,311,014 2,438,431 1,822,506 949,603 764,466 239,325 161,742 94,293 9,782,588 
Source: AIHW Population Database based on estimated resident population data compiled by ABS. 
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Table D6: Estimated resident female populations, states and territories, June 2002 
Age 
group NSW Vic Qld WA SA Tas ACT  NT  Australia 
0–4 209,998 149,393 120,635 61,267 44,412 14,878 10,193 8,471 619,365 
5–9 219,545 158,360 128,718 65,354 47,919 16,064 10,602 8,240 654,942 
10–14 222,365 160,854 130,986 68,209 48,895 16,673 11,090 7,690 666,903 
15–19 219,024 160,582 129,704 68,547 50,462 16,639 11,914 7,129 664,072 
20–24 215,476 164,600 125,384 65,016 47,029 14,105 13,331 7,456 652,455 
25–29 235,186 173,789 129,576 66,068 47,466 13,970 12,776 8,558 687,472 
30–34 254,762 195,255 140,697 73,271 53,979 16,314 13,161 9,154 756,676 
35–39 248,713 186,794 139,540 73,748 55,450 16,992 12,540 8,060 741,963 
40–44 255,317 187,635 143,484 75,781 58,882 18,600 12,938 7,521 760,266 
45–49 230,346 171,093 130,107 70,701 54,719 17,258 12,223 6,522 693,084 
50–54 215,417 160,557 123,151 64,600 52,781 16,242 11,745 5,655 650,212 
55–59 180,476 131,947 102,248 50,183 44,420 13,861 8,727 3,635 535,541 
60–64 143,193 105,156 77,891 39,445 34,713 11,236 5,845 2,325 419,844 
65–69 123,633 91,020 62,742 32,380 30,288 9,446 4,447 1,366 355,344 
70–74 117,855 85,628 57,482 28,694 29,724 8,816 3,725 978 332,914 
75–79 104,309 76,984 49,611 24,224 27,842 7,709 3,401 632 294,715 
80–84 75,377 54,172 36,110 17,269 20,125 5,744 2,266 422 211,487 
85+ 67,203 49,844 31,552 16,378 18,279 5,118 1,891 324 190,591 
Total  3,338,195 2,463,663 1,859,618 961,135 767,385 239,665 162,815 94,138 9,887,846 
Source: AIHW Population Database based on estimated resident population data compiled by ABS. 
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Appendix E: National Cervical Screening Programs 
contact list 
New South Wales 
Ms Jayne Ross 
Program Manager  
NSW Cervical Screening Program 
PO Box 533 
WENTWORTHVILLE  NSW 2145 
Phone: +61 2 9845 8046 
Fax: +61 2 9845 8047 
Email: jayne_ross@wsahs.nsw.gov.au 
Home page: www.csp.nsw.gov.au 
 
Western Australia 
Ms Nerida Steel 
Program Manager 
Cervical Cancer Prevention Program 
1st Floor, Eastpoint Plaza 
233 Adelaide Terrace 
PERTH WA 6000 
Phone: +61 8 9323 6730 
Fax: +61 8 9323 6711 
Email: nerida.steel@health.wa.gov.au 
Victoria  
Dr Heather Mitchell  
Medical Director  
Victorian Cervical Cytology Registry 
Email: hmitchel@vcs.org.au 
 
Mr Rory Wilby 
Program Manager 
Prevention & Child Health 
Dept of Human Services 
Level 17, 120 Spencer Street 
MELBOURNE Vic 3000 
Phone: +61 3 9637 4130 
Fax: +61 3 9637 4653 
Email: rory.wilby@dhs.vic.gov.au 
Home page: www.dhs.vic.org.au 
 
Tasmania 
Ms Gail Raw 
Program Manager 
Dept of Health & Human Services 
GPO Box 125B 
HOBART Tas 7001 
 
Mr Paul Chandler 
Data Manager 
Phone: +61 3 6230 7753 
Email: paul.chandler@dchs.tas.gov.au 
Home page: www.dchs.tas.gov.au 
 
Queensland 
Ms Jennifer Muller 
Program Manager 
Women’s Cancer Screening Services 
Queensland Health 
PO Box 48 
BRISBANE Qld 4001 
Phone: +61 7 3234 0905 
Fax: +61 7 3235 2629 
Email: Jennifer_muller@health.qld.gov.au 
South Australia 
Ms Sue Gilchrist 
Program Manager  
SA Cervical Screening Program 
2nd Floor, Norwich Centre 
55 King William Road 
NORTH ADELAIDE SA 5006 
Phone: +61 8 8226 8182 
Fax: +61 8 8226 8190 
Email: sue.gilchrist@dhs.sa.gov.au 
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Australian Capital Territory 
Ms Helen Sutherland 
Program Manager 
ACT Health 
GPO Box 825 
CANBERRA ACT 2601 
Phone: +61 2 6205 1540 
Fax: +61 2 6205 1394 
Email: helen.sutherland@act.gov.au 
 
Mr Peter Couvee 
Database Manager/Coordinator 
ACT Cervical Cytology Register 
ACT Community Health 
GPO Box 825 
Canberra ACT 2601 
Phone: +61 2 6205 1955 
Fax: +61 2 6205 5035 
Email: peter.couvee@act.gov.au  
 
Northern Territory 
Ms Vera McMahon 
Program Coordinator 
Well Women’s Cancer Prevention Program 
Territory Health Services 
PO Box 40596 
CASUARINA NT 0810 
Phone: +61 8 8922 6445 
Fax: +61 8 8922 5511 
Email: vera.mcmahon@nt.gov.au 
 
Mr Guillermo Enciso 
Data Manager 
Casuarina Health Services Centre 
Territory Health Services 
PO Box 40596 
CASUARINA NT 0810 
Phone: +61 8 8922 6441 
Fax: +61 8 8922 6447 or 6455 
Email: Guillermo.enciso@nt.gov.au 
 
Australian Government Department of 
Health and Ageing 
Screening and Family Planning Section 
Department of Health and Ageing 
GPO Box 9848 
CANBERRA ACT 2601 
Fax: 61 2 6289 4021 
Home page: 
www.cervicalscreen.health.gov.au 
 
 
 
 
 

  
 
Appendix F: NHMRC guidelines for the management of women with screen-
detected abnormalities (under review) 
This reference sheet is a summary of the NHMRC guidelines for the management of women with screen-detected abnormalities. It is intended to 
assist medical practitioners to take appropriate action on receipt of Pap smear reports. In 2004 the NHMRC commenced a review of these guidelines.
Low-grade epithelial abnormalities 
Pap smear report Investigation Management 
Non-specific minor squamous cell 
changes/atypia 
 Repeat smear at 12-monthly intervals until it reverts to normal. 
Minor changes in endocervical cells/ low-grade 
glandular change 
Repeat smear in 6 months using cytobrush and spatula. If low-
grade abnormality persists, refer for colposcopy and biopsy if 
indicated. 
If endocervical cell abnormality confirmed, refer to gynaecologist for 
appropriate treatment. 
HPV effect/HPV-associated cell changes Repeat smear at 6-monthly intervals. If HPV-associated cell 
changes persist after 12 months, refer for colposcopy. 
If HPV confirmed, continue with 6 monthly smears until 2 negative 
reports are received. Repeat smear annually for 2 years then revert 
to 2-yearly screening. 
Possible CIN 1 ± HPV/possible mild dysplasia Repeat smear at 6-monthly intervals until 2 successive negative 
reports are received. If lesion persists for 12 months, refer for 
colposcopy. 
If CIN 1 confirmed, follow either observational or active 
management program as explained on reverse of sheet. 
CIN 1 ± HPV/mild dysplasia Refer for colposcopy and biopsy if indicated. If CIN 1 confirmed, follow either observational or active 
management program as explained on reverse of sheet. If higher 
grade abnormality diagnosed, see below. 
High-grade epithelial abnormalities 
Pap smear report Investigation Management 
CIN 2 ± HPV/moderate dysplasia Refer for colposcopy and directed biopsy. If CIN 2 confirmed, treatment by gynaecologist with appropriate 
expertise is required. 
CIN 3 ± HPV/severe dysplasia Refer for colposcopy and directed biopsy. If CIN 3 confirmed, treatment by gynaecologist with appropriate 
expertise is required. 
CIN 3 ± HPV with possible invasion; 
Endocervical glandular dysplasia; or 
Adenocarcinoma in situ 
Refer to gynaecologist with expertise in colposcopic evaluation of 
malignancies. 
Treatment by gynaecologist with appropriate expertise is required. 
Invasive squamous cell carcinoma (SCC) or 
Adenocarcinoma 
Refer to gynaecologist skilled in the management of malignancies, 
or a specialist unit, for urgent evaluation and management. 
Treatment by gynaecologist with appropriate expertise is required. 
Inconclusive – abnormal cells highly suggestive 
but not diagnostic of a high-grade abnormality 
Refer for colposcopy and possible biopsy, unless there is an 
obvious diagnostic difficulty e.g. epithelial atrophy or infection. In 
this case, treat the problem and repeat the smear. 
If high-grade lesion confirmed, treatment by gynaecologist with 
appropriate expertise is required. 
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Management of women with low-grade epithelial abnormalities 
A cytological assessment of CIN 1 requires referral for colposcopy and, if indicated, biopsy. There is controversy over the management—observational and active. Both treatment 
options should be fully discussed with the woman. 
Observational management 
If the diagnosis of CIN 1 is confirmed and the woman elects not to be treated, cervical smears should be taken at 6-monthly intervals until the abnormality either regresses or 
progresses. After 2 negative smears at 6-monthly intervals, smears should be taken at yearly intervals. If two consecutive annual smears are normal the woman can revert to 2-yearly 
screening. 
Active management 
Treatment by an accepted method, either ablative or excisional. 
 
Pap smear report Management 
Negative/within normal limits Repeat smear in 2 years. 
Negative/within normal limits and no endocervical cells 
present 
Repeat smear in 2 years. 
Negative with inflammation Repeat smear in 2 years. 
Note: Investigate any symptoms that are not readily explained, such as post-coital or intermenstrual bleeding. A negative Pap smear must not be taken as reassurance in these 
circumstances. Further investigation may involve referral to a gynaecologist. 
Unsatisfactory Repeat smear in 6–12 weeks, with treatment and where possible correction of any problems beforehand if appropriate. 
 
Post-treatment assessment 
After initial post-treatment colposcopic assessment by gynaecologist, repeat smear at 6-monthly intervals for 1 year. 
Following treatment of a high-grade epithelial abnormality, smears should be repeated yearly thereafter. Following 
treatment for a low-grade epithelial abnormality, revert to normal 2-yearly screening after 2 consecutive normal smears at 
yearly intervals.  
Special circumstances  
Total hysterectomy for CIN Annual smears from vaginal vault for 5 years, then revert to 2-yearly smears. 
Total hysterectomy for benign causes No further smears required if previous smears were negative. Baseline smear if reason for hysterectomy and/or previous 
Pap smear history unknown. 
Subtotal hysterectomy for benign causes—cervix 
present 
Continue normal 2-yearly screening. 
Abnormality during pregnancy Refer for colposcopy during 1st trimester to exclude invasive disease. If confirmed high-grade abnormality, repeat 
colposcopy during mid-trimester to exclude progression. Lesion should be reassessed 8 weeks post-partum. 
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Glossary  
Ablative therapy: the destruction of cells on the surface of the cervix using laser therapy, 
chemicals or diathermy. 
ABS: Australian Bureau of Statistics. 
ACT: Australian Capital Territory—a land-locked territory of Australia situated within the 
state of New South Wales on the eastern seaboard with a population of 319,317 (2001). Its 
capital city is Canberra, which is also Australia’s capital city. 
Adeno-squamous: a mix of adenocarcinoma and squamous cells in the same sample. 
Adenocarcinoma: a cancer formed from the cells of a gland. 
Adjuvant: enhancing or administered to enhance the effectiveness of a treatment or 
substance. 
AHMAC: Australian Health Ministers’ Advisory Council. 
AIHW: Australian Institute of Health and Welfare. 
ASGC: Australian Standard Geographical Classification: the classification designed by the 
ABS to define the geography of Australia. 
AS rate: age-standardised rate 
Atypia: the condition of being irregular. 
Basement membrane: the delicate, non-cellular layer on which an epithelium is seated. The 
epithelium forms the surface portion of the skin and lines hollow organs and all passages of 
the respiratory, digestive and genito-urinary systems. 
Benign: not malignant. 
Cancer (malignant neoplasm): a term used to describe one of several diseases which result 
when the process of cell division, by which tissues normally grow and renew themselves, 
becomes uncontrolled and leads to the development of malignant cells. These cancer cells 
multiply in an uncoordinated way, independently of normal growth control mechanisms, to 
form a tumour. This tumour may expand locally by invasion or systemically by metastasis 
via the lymphatic or vascular systems. If left untreated, most malignant tumours will 
eventually result in death. 
Cancer death: a death where the underlying cause is indicated as cancer. Persons with cancer 
who die of other causes are not counted in the death statistics in this publication. 
CIN (cervical intraepithelial neoplasia): squamous cell carcinoma of the cervix is mostly 
preceded, over a period of years, by a spectrum of asymptomatic abnormalities known as 
cervical intraepithelial neoplasia (CIN) graded as CIN 1 (mild dysplasia), CIN 2 (moderate 
dysplasia) and CIN 3 (severe dysplasia and carcinoma-in-situ). CIN usually occurs at least a 
decade before cervical cancer. If CIN remains untreated, some women will develop cervical 
cancer and others will progress to invasive cervical cancer, despite treatment (Jelfs 1995). 
Cone biopsy: biopsy in which an inverted cone of tissue is excised, as from the uterine 
cervix. 
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Colposcopy: an examination of the lower genital tract with a magnifying instrument called a 
colposcope. This method of conservative evaluation allows the clinician to more accurately 
assess the cytologic abnormality by focusing on the areas of greatest cellular abnormality and 
by sampling them with a punch biopsy to attain diagnosis. 
Cryosurgery: the destruction of tissue using extreme cold. 
Dysplasia: abnormal cell growth. 
Endocervical: the inside of the uterine cervix or the mucous membrane lining of the cervix.  
Epidemiology: the quantitative study of the distribution and determinants of health-related 
states and events in populations, and the application of this study to the control of health 
problems. 
Epithelium: the covering of internal and external surfaces of the body, including the lining of 
vessels and other small cavities. It consists of cells joined by small amounts of cementing 
substances. It is classified into types on the basis of the number of layers deep and the shape 
of the superficial cells. 
Exfoliate: to break away or remove. 
HGA: high-grade abnormalities as defined for this report include CIN 1/2, CIN 2, CIN 3 or 
adenocarcinoma-in-situ. 
Histology: the microscopic study of the minute structure and composition of tissues. 
Hysterectomy: the surgical procedure whereby all or part of the uterus is removed. 
Hysterectomy fractions: the proportion of women who have had their uterus removed by 
hysterectomy. 
HPV: human papilloma virus. 
ICD-10: International Classification of Disease—a coding system used to identify the primary 
site of the malignancy. This classification is in its tenth revision. 
Incidence: see new cancer case 
Intraepithelial: the area within the layer of cell tissues forming the epidermis of a body 
cavity. These cells comprise contiguous cells having minimum intercellular substance. 
Invasive cancer: a tumour whose cells have a tendency to invade healthy or normal tissues. 
LGA: low-grade abnormalities include atypia, warty atypia (human papilloma virus (HPV) 
effect), possible CIN, equivocal CIN, CIN 1 or endocervical dysplasia not otherwise specified 
(NOS). 
Lymph node: masses of lymphatic tissue, often bean-shaped, that produce lymphocytes and 
through which lymph filters. These are located throughout the body. 
Malignant: abnormal changes consistent with cancer. 
Metastasis: the process by which a disease is transferred from one part of the body to 
another, for example via the lymphatic system or the bloodstream. 
Mortality: see cancer death. 
Neoplasia: the process by which tumours are formed. 
New cancer case: a person who has a new cancer diagnosed for the first time. One person 
may have more than one cancer and therefore may be counted twice in incidence statistics if 
it is decided that the two cancers are not of the same origin. This decision is based on a series 
of principles set out in more detail in a publication by Jensen et al. (1991). 
NOS: not otherwise specified. 
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NSW: New South Wales—a state of Australia on the eastern seaboard which has the largest 
state capital city in Australia, Sydney, and a population of 6,575,217 (2001). 
NT: Northern Territory—a territory in the north of Australia with a population of 197,768 
(2001) and Darwin as its capital city. 
Pap smear: a test prepared for the study of exfoliated cells from the cervix (refer to  
Appendix A). 
Post-partum: following childbirth. 
Qld: Queensland—a state in the north-east of Australia with a population of 3,628,946 (2001) 
and Brisbane as its capital city. 
Radiation therapy: the treatment of disease with any type of radiation, most commonly with 
ionising radiation, such as X-rays, beta rays and gamma rays. 
RRMA: Rural, Remote and Metropolitan Areas Classification. 
SA: South Australia—a state in the southern part of Australia with a population of 1,511,728 
(2001) and Adelaide as its capital city. 
Screening: the performance of tests on apparently well people in order to detect a medical 
condition at an earlier stage than would otherwise be the case. 
Sensitivity: the proportion of individuals with the disease whom the screening test labels 
positive. 
Squamous malignancy: cervical cancer can be derived from several cell types. One of these 
cell types is the squamous cell and most cervical cancers are derived from this cell type. 
Stroma: the supporting framework of an organ. 
Tas: Tasmania—an island state in the south-east of Australia with a population of 471,795 
(2001) and Hobart as its capital city. 
The Institute: the Australian Institute of Health and Welfare. 
Vic: Victoria—a state in the south-east of Australia with a population of 4,804,726 (2001) and 
Melbourne as its capital city. 
WA: Western Australia—the largest state in Australia, located in the west with a population 
of 1,901,159 (2001) and Perth as its capital city. 
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